

## Curriculum Vitae

**Date Prepared:** 7/7/2014

**Name:** Anne Eden Evins, M.D., M.P.H.

**Office Address:** MGH Center for Addiction Medicine  
60 Staniford Street, Boston, MA 02114

**Home Address:** 684 Sudbury Road, Concord, MA 01742

**Work Phone:** 617-643-4679

**Work Email:** [a\\_eden\\_evins@hms.harvard.edu](mailto:a_eden_evins@hms.harvard.edu)

**Work FAX:** 617-643-1998

**Place of Birth:** Durham, North Carolina

## Education

09/82 - 05/86	B.A.	University of Virginia	Charlottesville, VA
07/87 - 06/91	M.D.	Medical University of South Carolina	Charleston, SC
07/02 - 06/05	M.P.H.	Harvard School of Public Health	Boston, MA

## Postdoctoral Training

07/91 - 06/92	Intern in Pediatric Medicine	Children's National Medical Center	Washington, D.C.
07/92 - 06/94	Resident in Psychiatry	Massachusetts Mental Health Center	Boston, MA
07/94 - 06/95	Resident in Psychiatry	Harvard Longwood Psychiatry Residency Training Program	Boston, MA

## Faculty Academic Appointments

07/91 - 06/92	Clinical Fellow in Pediatric Medicine	George Washington University School of Medicine	Washington, D.C.
07/92 - 06/96	Clinical Fellow in Psychiatry	Harvard Medical School	Boston, MA
07/94 - 06/95	Fellow, Molecular Neurogenetics Laboratory	McLean Hospital (Rachael Neve, PhD)	Belmont, MA

07/95 - 06/96	Fellow, Schizophrenia Clinical and Research Program	Massachusetts General Hospital (Donald C. Goff, MD)	Boston, MA
07/96 - 06/01	Instructor in Psychiatry	Harvard Medical School	Boston, MA
07/01 - 06/06	Assistant Professor of Psychiatry	Harvard Medical School	Boston, MA
07/07 – 12/13	Associate Professor of Psychiatry	Harvard Medical School	Boston, MA
01/14 – present	William Cox Family Associate Professor of Psychiatry in the Field of Addiction Medicine	Harvard Medical School	Boston, MA

### **Appointments at Hospitals / Affiliated Institutions**

1995 - 2006	Clinical Assistant in Psychiatry	Massachusetts General Hospital	Boston, MA
2006 - 2008	Assistant Psychiatrist, Department of Psychiatry	Massachusetts General Hospital	Boston, MA
2008 - 2010	Associate Psychiatrist, Department of Psychiatry	Massachusetts General Hospital	Boston, MA
2010 - Present	Psychiatrist, Department of Psychiatry	Massachusetts General Hospital	Boston, MA

### **Other Professional Positions**

1995 - 1998	Attending Psychiatrist, Acute Psychiatry Service	Massachusetts General Hospital	Boston, MA
1995 - 2005	Attending Psychiatrist, Freedom Trail Clinic	Erich Lindemann Mental Health Center	Boston, MA
1996 - 1998	Attending Psychiatrist, Acute Inpatient Unit	Erich Lindemann Mental Health Center	Boston, MA
1998 - 2002	Attending Psychiatrist, Bipolar Treatment & Research Center	Massachusetts General Hospital	Boston, MA
2004 – 2007	Psychiatrist, Depression Clinical and Research Program	Massachusetts General Hospital	Boston, MA

## **Major Administrative Leadership Positions**

### **Local**

07/93 - 06/94	Chief Resident	Harvard Longwood Psychiatry Residency Training Program, Inpatient Psychotic Disorders Unit
07/05 - 06/09	Director	Massachusetts General Hospital Psychiatry Residency Training Module in Addictive Disorders
07/05 - Present	Director	MGH Addiction Research Program
09/05 - Present	Director	MGH Addiction Research Fellowship
09/05 - Present	Director, MGH Site	Harvard Medical School Clinical Addiction Psychiatry Fellowship
07/05 - 07/08	Director, Addiction Module	MGH PGY-3 Resident Education Program
07/07 - Present	Director	MGH, Center for Addiction Medicine

## **Committee Service**

### **Local**

1994 - 1995	Harvard Longwood Psychiatry Residency Training Program Curriculum Development Committee	Resident Member
1994 - 1995	Biological Mechanisms in Psychiatry Course, Harvard Longwood Psychiatry Residency Training Program Curriculum Development Committee	Resident Member
1994 - 1995	Consolidated Department of Psychiatry, Harvard Medical School, Harvard Psychiatry Residents Teaching Day Planning Committee	Resident Member
1998 - 2010	Harvard Medical School Working Group on Tobacco Control	Member
1999 - 2008	MGH Department of Psychiatry Junior Faculty Committee	Member
2005 - Present	Harvard Clinical Addiction Psychiatry Fellowship Training Committee	Member
2000 - Present	MGH Department of Psychiatry Steering Committee	Member
2003 - 2010	Harvard Medical School Department of Psychiatry Mysell Committee	Member 2005 – 2010 Chair, 2006 - 2007
2006 - Present	MGH Department of Psychiatry Research Committee	Member

2009 - Present	Harvard Medical School Clinical Addiction Psychiatry Fellowship Program Faculty Training Committee	MGH Site Director
2009 - Present	Harvard Medical School Foundation Funds Review Subcommittee 2	Faculty Reviewer
2011 - Present	MGH Department of Psychiatry Adult Clinical Research Steering Committee	Member
2011 - Present	Massachusetts General Hospital Clinical Research Council	Department of Psychiatry Representative
2012 - Present	Massachusetts General Hospital Continuous Research Operations Improvement Taskforce: Clinical Research Workgroup	Department of Psychiatry Representative
2013-2017	NIAAA R01 AA019664: Recovery from Addictions Among Youth	Medical Monitor
2014 - Present	MGH/McLean Psychiatry Residency Program	Research Concentration Program Advisory Group

### **Committee Service**

#### **Regional**

1995 - 2007	Central Office Research Review Committee, Commonwealth of Massachusetts Department of Mental Health	Physician Member
1996 - 1998	Utilization Review Committee, Erich Lindemann Mental Health Center, Commonwealth of Massachusetts Department of Mental Health	Physician Advisor
1996 - 1998	Research Review Committee, Erich Lindemann Mental Health Center, Commonwealth of Massachusetts Department of Mental Health	Physician Advisor
1999 - 2001	Advisory Committee for the Development of Clinical Practice Guidelines for the Treatment of Bipolar Affective Disorder in Adults, Commonwealth of Massachusetts Department of Mental Health and Executive Office of Health and Human Services Committee	Physician Advisor and Author
2001 - 2003	Advisory Committee for the Development of Clinical Practice Guidelines for Psychiatrists for Preventive Medical Management of Patients with Major Mental Illness, Commonwealth of Massachusetts Executive Office of Health and	Physician Advisor and Author

## Human Services

2010 - 2015	Data Safety Monitoring Board for the Multicenter NIMH TRIAD study. Principal Investigator: Steve Safren, PhD	Chair
2013 - 2018	Data Safety Monitoring Board R01DA036486, Manipulating Tobacco Constituents in Female Menthol Smokers University of Connecticut	Chair

## **Committee Service**

### **National and International**

1999 - 2001	Pathway Leader Committee, NIMH sponsored Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)	Co-chair
1999 - 2001	National Institute for Mental Health STEP-BD Advisory Committee for Schizoaffective Disorder Treatment Pathway	Chair
2004	NIH Grant Review Study Section National Institute for Mental Health IRG ZMH1 SRC(99) Special Emphasis Panel	Primary Reviewer
2004 - 2007	NIH / National Institute for Mental Health Treatment Units for Research on Neurocognition in Schizophrenia (NIMH TURNS TMU)	Member
2005	NIH Study Section National Institute for Mental Health IRG ZMH 1 ERB-B(03) Special Emphasis Panel	Primary Reviewer
2007 - 2011	NIDA Intramural Program	Primary External Reviewer
2008 - 2010	Schizophrenia Patient Outcomes Research Team (PORT) Sponsored by the National Institute for Mental Health	Expert Panel Member to Update Treatment Recommendations
2008 - 2009	NIH Study Section Medication Development Research Subcommittee (NIDA-L)	Primary Reviewer

2008	NIH Study Section National Institute on Drug Abuse Risk Prevention and Interventions for Addictions (RPIA) Study Section	Primary Reviewer
2008	NIH Study Section Special Emphasis Panel: Pilot Clinical Trials of Pharmacotherapies for Substance Related Disorders (R01) RFA-DA09-005 ZDA1 SXC-E	Primary Reviewer
2008	NIH Study Section National Institute on Drug Abuse Special Emphasis Panel: Transdisciplinary Prevention Research ZDA1 MXG-S (07)	Primary Reviewer
2009	NIDA Advisory Committee Development of NIDA RFA: 'Validation of <i>in vivo</i> Screening for Drug Discovery and Development: Focus on Smoking Cessation',	Scientific Advisor to NIDA
2009	NIH Study Section National Institute on Drug Abuse Special Emphasis Panel ZDA1 GXM-A (06) 1	Primary Reviewer
2009 - present	NIH Study Section National Institute on Drug Abuse  Support for Conferences and Scientific Meetings PA-10-071 (Parent R13/U13) Two cycles per year	Primary Reviewer all years Chair, March 2014 review
2009 - 2010	Florida Department of Health Bureau of Tobacco Prevention Program	Primary Reviewer
2009 - 2011	James and Esther King Biomedical Research Program	Expert Reviewer
2010 - 2012	National Alliance for Mental Illness	Scientific Council Physician Member
2011	National Cancer Institute Cancer Center Cooperative Grant Memorial Sloan Kettering U54 CA137788	Expert External Reviewer
2011	NIH Study Section National Institute on Drug Abuse RFA:	Primary Reviewer

'Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence' (STTR [R41])

2011 - 2013	NIH Study Section National Institute on Drug Abuse Grand Opportunity in Medications Development for Substance Related Disorders (U01) NIDA PAR-11-109	Primary Reviewer
2011	NIH Study Section National Institute on Drug Abuse Special Emphasis Panel ZDA1 GXM-A 05  Reviewing responses to FOA's: NIDA Medications Development for the Treatment of Pregnant/Postpartum Women and/or In Utero Substance Exposed Neonates (R01) PA09-106  NIDA Behavioral & Integrative Treatment Development Program (R34) PA10-013  NIDA Pilot Feasibility Studies in Preparation for Drug Abuse Prevention Trials (R34) PA-09-146	Chair
2011 - 2012	Expert panel review convened by SRI International to review a novel comprehensive, patient-centered smoking cessation intervention using enhanced behavioral intervention and internet based advice to be proposed to NIDA	Expert Panel Member
2011	NIH Study Section NIDA Drug Abuse Prevention Intervention Research (R01) PA-08-217	Primary Reviewer
2011	NIH Study Section NIDA Collaborative Clinical Trials in Drug Abuse (Collaborative R01) PAR-10-099	Primary Reviewer
2012	Hong Kong SAR Government – Health and Health Services Research Fund	Expert External Reviewer
2012	NIH Study Section NIDA PA-12-212 NIH Support for Scientific Meetings	Chair

2012	NIH Study Section NIDA PA-12-223 Research on Children in Military Families: The Impact of Parental Military Deployment and Reintegration on Child and Family Functioning	Primary Reviewer
2012 - present	Nominations Committee Society for Research on Nicotine and Tobacco	Chair
2012	Ontario Mental Health Foundation: Pharmacogenetics of Nicotine Addiction in Schizophrenia	Invited Expert External Reviewer
2012 – 2013	Program Committee 19th Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT), Triennial International Conference	International Program Committee Member
2013	Speaker NIDA/NIMH/NCI Workshop on smoking cessation for people with schizophrenia	Invited participant and speaker
2013	NIH Study Section NIDA 2013/10 ZDA1 MXL-F (07) Special Emphasis Panel/Scientific Review Group	Primary Reviewer
2013	NIH Study Section National Institute on Drug Abuse NIDA Special Emphasis Panel/Scientific Review Group Eureka FOA: RFA-NS-13-007: Exceptional Unconventional Research Enabling Knowledge Acceleration (EUREKA) for Neuroscience and Disorders of the Nervous System (R01)	Primary Reviewer
2013	NIH Study Section National Institute on Drug Abuse (NIDA) ZRG1 PSE (03) Special Emphasis Panel/Scientific Review Group Behavioral Genetics and Epidemiology Study Section	Primary Reviewer
2013 – 2015	Clinical Program Committee Annual Meeting of the Society for Research on Nicotine and Tobacco (SRNT)	Program Committee Member



2013	Advisory Board Smart Approached to Marijuana: A Project of the Policy Solutions Lab	Advisory Board Member
2013 - 2015	Program Committee Annual meeting of the American Society of Clinical Psychopharmacology	Program Committee Member
2013-2018	Data Safety Monitoring Board NIDA P50 DA036114 Tobacco Center of Regulatory Research (TCOR) University of Vermont, Brown, Johns Hopkins University	Chair
2013	American College of Neuropsychopharmacology 2013 Annual Meeting: $\alpha 4\beta 2$ -Nicotinic Acetylcholine Receptors in Schizophrenia: Implications for Smoking Cessation and Therapeutics	Panel Chair
2013-2018	Data Safety Monitoring Board NIDA P50 DA036114, Tobacco Center of Regulatory Research (TCOR) University of Vermont, Brown University, Johns Hopkins University	Chair
2014	NIH Study Section National Institute on Drug Abuse (NIDA)'s Cutting- Edge Basic Research Awards (CEBRA) program PAR-12-086	Primary Reviewer
2014	NIH Study Section Special Emphasis Panel to review responses to two funding opportunity announcements: PA-11-311: Drug Abuse Prevention Intervention Research (R01) and PA-13-077: Behavioral & Integrative Treatment Development Program (R01)	Primary Reviewer
2014	NIH Study Section Scientific Review Group: ZDA1 HXO-H 09 S, Multi-site Clinical Trials SEP II	Primary Reviewer
2014-2019	Data Safety Monitoring Board Center for the Evaluation of Nicotine in Cigarettes	Physician member of the five member board

U54 DA 031659 (CENIC)  
 Overseeing Three Clinical Trials, conducted at 12 sites in the US, with Principal Investigators based in the University of Minnesota and University of Pittsburgh

2014	The City College of New York (CCNY) and Memorial Sloan-Kettering Cancer Center (MSKCC) specialized cooperative grant program	Expert External Reviewer U54 Pilot Research Grant Program
2014	NIH Study Section Special Emphasis Panel for Biobehavioral Regulation, Learning and Ethology (BRLE)	Primary Reviewer

**Professional Societies**

1999 – Present	Society for Research on Nicotine and Tobacco	Member
2012 - Present		Chair, Nominating Committee
2009 - Present	College on Problems of Drug Dependence	Elected Member
2011 - Present	American College of Neuropsychopharmacology	Elected Member
2012 - Present	Roxbury Society for Medical Improvement	Elected Member

**Editorial Boards**

2010 – present	Journal of Dual Diagnosis
2011 – present	The Scientific World Journal
2013 – present	Current Psychiatry Reviews
2014 – present	Journal of Schizophrenia Research

## **Ad hoc reviewer**

Addiction  
Administration and Policy in Mental Health and Mental Health Services Research  
American Journal of Psychiatry  
JAMA Psychiatry (Archives of General Psychiatry)  
Biological Psychiatry  
British Journal of Psychiatry  
BMC Medicine  
BMC Psychiatry  
Clinical Schizophrenia and Related Psychoses  
CNS Drugs  
  
Comprehensive Psychiatry  
Current Psychiatry  
Drug and Alcohol Dependence  
European Archives of Psychiatry and Clinical Neuroscience  
European Psychiatry  
Expert Opinion on Pharmacotherapy  
Expert Review of Neurotherapeutics  
Harvard Review of Psychiatry  
Human Psychopharmacology: Clinical and Experimental  
International Journal of Developmental Neuroscience  
International Journal of Neuropsychopharmacology  
International Journal of Social Science & Medicine  
Journal of the American Medical Association (JAMA)  
Journal of Clinical Psychiatry  
Journal of Clinical Psychopharmacology  
Journal of Consulting and Clinical Psychology  
Journal of Dual Diagnosis  
Journal of Mental Health  
Journal of Nervous and Mental Disease  
  
Journal of Psychopharmacology  
Medscape  
  
Neuropharmacology  
Neuropsychopharmacology  
Nicotine and Tobacco Research  
Pharmacology, Biochemistry and Behavior  
Physiology and Behavior  
PLOS ONE  
Primary Psychiatry  
Progress in Neuro-Psychopharmacology & Biological Psychiatry  
Psychiatric Rehabilitation Journal  
Psychiatry Research  
Psychiatry Research: Neuroimaging  
Psychiatric Services  
  
Psychopharmacology  
Psychosomatics  
Schizophrenia Research  
Schizophrenia Bulletin  
Social Science and Medicine  
  
The Lancet  
The Lancet Diabetes and Endocrinology  
The Lancet Infectious Diseases  
The Lancet Neurology  
The Lancet Oncology  
The Lancet Respiratory Medicine  
Trends in Cognitive Sciences  
World Journal of Biological Psychiatry

## Honors

1990	Chairman's Award	Medical University of South Carolina
1993	Teaching Award	Harvard Medical School Psychiatry Clerkship Honorable Mention
1994	Harvard Longwood Psychiatry Program Travel Award	Harvard Longwood Psychiatry Program Travel award to leadership course for residents at Emory
1996	Young Investigator Award	National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD)
1998	New Investigator Award	NIMH-New Clinical Drug Evaluation Unit (NCDEU)
1999	Young Investigator Award	National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD)
2000	Young Scholar Award	Commonwealth of Massachusetts Department of Public Health and Tobacco Control Board
2000	Annual Gala Invited Speaker	National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD)
2005	Psychiatry Research Award	MGH Research Day Massachusetts General Hospital
2007	Research Selected one of 10 Clinical Research Hot Topics	American College of Neuropsychopharmacology (ACNP) 46 <sup>th</sup> Annual Meeting, Boca Raton, FL
2009	Research Selected for 'Rapid Response' Paper Session	Society for Research on Nicotine and Tobacco (SRNT) 15 <sup>th</sup> Annual Meeting, Dublin, Ireland
2009	Partners in Excellence Award to MGH Center for Addiction Medicine and Addiction Research Program	Partners Healthcare
2011	Award for Excellence in Mentoring in the Research Arena	MGH Department of Psychiatry
2013	Partners in Excellence Award to MGH Center for Addiction Medicine for Leadership and Innovation	Partners Healthcare

## Report of Funded and Unfunded Projects

### Completed Funding

1996 – 1998	National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD) Young Investigator Award	PI	<p>Young Investigator Award: Glycine augmentation of clozapine treatment for negative symptoms of schizophrenia</p> <p>\$60,000 total direct costs</p> <p>The major aim of this double blind, placebo controlled trial of glycine added to clozapine patients with negative symptoms of schizophrenia was to evaluate the effect on negative symptoms and cognitive function and further our understanding of NMDA hypofunction in the pathophysiology of negative symptoms and cognitive dysfunction in schizophrenia.</p>
1998 - 2001	Stanley Foundation Research, NAMI Research Institute Award	Co-I (Sachs)	<p>A double-blind placebo-controlled trial of inositol augmentation for bipolar depression.</p> <p>\$150,170 total costs</p> <p>The major aim of this project was to test in a double-blind, placebo controlled trial whether inositol added efficacy to mood stabilizer treatment in adults with treatment refractory bipolar depression.</p>
1999 - 2001	Pfizer Investigator Initiated Award	PI	<p>Donepezil vs. placebo added to mood stabilizer treatment for treatment resistant mania and rapid cycling.</p> <p>\$267,773 total costs</p> <p>The major aim of this project was to test in a double-blind, placebo controlled trial whether donepezil added efficacy to mood stabilizer treatment in adults with treatment refractory mania, rapid cycling and ultra-rapid cycling.</p>
1999 – 2001	NARSAD Young Investigator Award	PI	<p>Double blind placebo controlled trial of low dose bupropion for smoking cessation in schizophrenia</p> <p>\$60,000 total direct costs</p> <p>Nearly 90% of adults with schizophrenia smoke cigarettes compared to less than 25% of the general U.S. adult population. Compounded by the problem that patients with schizophrenia are less likely to</p>

receive adequate routine and preventative medical care, including smoking cessation treatment, heavy smoking represents a significant and neglected public health problem for people with schizophrenia. The major aims of this double blind, placebo controlled trial of low dose bupropion SR for smoking cessation in adult smokers with schizophrenia was to establish safety with regard to psychiatric symptoms and efficacy for tobacco abstinence.

1999 – 2001 NIDA R03 DA12542 PI

SR bupropion for smoking cessation in schizophrenia.

\$100,000 total direct costs

Smoking cessation schizophrenia has received little attention. Nicotine replacement therapy is only modestly effective, roughly equivalent to placebo quit rates in non-psychiatric patients. Low dose bupropion was superior to placebo for smoking cessation in our previous trial in smokers with schizophrenia. The major aims of this double blind, placebo controlled trial in adult smokers with schizophrenia is to establish safety with regard to psychiatric symptoms and efficacy for tobacco abstinence of full dose bupropion SR (150 mg bid) for smoking cessation.

2000 – 2003 Massachusetts Department of Public Health Research Grant Award PI

SR bupropion and cognitive behavioral therapy for smoking cessation in schizophrenia

\$125,000 total direct costs

The major aims of this double blind, placebo controlled trial of bupropion SR (150 mg bid) for smoking cessation in adult smokers with schizophrenia is to extend our prior findings with this treatment on safety with regard to psychiatric symptoms and efficacy for tobacco abstinence.

2001 – 2006 NIDA K23 DA00510 PI

Nicotine and smoking cessation in schizophrenia

\$800,465 total costs

The major goal of this mentored training grant was to provide Dr. Evins with the expertise needed to bridge several disciplines in the study of pharmacologic and behavioral interventions in the treatment of nicotine addiction in schizophrenia through formal study of biostatistics, epidemiology

			and clinical effectiveness at the Harvard School of Public Health and to conduct of a randomized clinical trial of bupropion and a modified 12 week group cognitive behavioral therapy smoking cessation intervention.
2003 - 2005	Investigator Initiated Grant from Janssen Pharmaceuticals	PI	<p>Double-blind, placebo-controlled trial of the nicotinic agonist galantamine for treatment of cognitive impairment in non-smokers with schizophrenia.</p> <p>Prevalence of nicotine dependence in adults with schizophrenia is high. Benefits of nicotine to patients with schizophrenia include reversal cognitive deficits. Nicotine improves learning, visual and spatial working memory, attention, auditory sensory gating smooth pursuit eye movements and reaction time, and the effects appear to persist or improve over time. The aim of this study was to conduct a randomized controlled trial of the effects of the acetylcholinesterase inhibitor, galantamine, on cognitive deficits in schizophrenia.</p>
2004 - 2013	DHHS SAMHSA 05B1MACMHS	PI	<p>Treatment strategies for smoking cessation in patients with schizophrenia</p> <p>\$115,000 direct costs per year</p> <p>This funding supported development of a smoking cessation treatment consortium with the aim of developing safe and effective smoking cessation interventions for people with major mental illness.</p>
2004 – 2006	Stanley Medical Research Institute	PI	<p>A double-blind placebo-controlled trial of the effects of transdermal nicotine on cognitive function in non-smokers with schizophrenia.</p> <p>\$130,334 total direct costs</p> <p>The major aim of this project was to evaluate the effectiveness of transdermal nicotine compared with placebo for attentional impairment in patients with schizophrenia and in those without psychiatric illness</p>
2004 - 2006	Sidney R. Baer Foundation Grant	Co-I (Goff)	<p>Enhancing the clinical care of individuals diagnosed with schizophrenia</p> <p>The major goals of this project were to develop interventions and educational tools to improve the physical health of people with schizophrenia</p>

2004 - 2006	Investigator Initiated Grant from Janssen Pharmaceuticals	PI	<p>Effects of risperidal consta on cocaine craving, use, and neural substrates of reward</p> <p>\$352,670</p> <p>Dopamine blocking agents have shown efficacy for treatment of cocaine dependence in animals but have failed in clinical trials in humans. This may be due to non-adherence with study treatment. This trial aimed to evaluate whether a long acting injectable form of risperidone reduced cocaine craving, cocaine use, and neural substrates of reward activation to cocaine cues.</p>
2006 – 2008	Bowman Family Foundation	PI	<p>Varenicline as a probe of the role of nicotinic acetylcholine receptor function in cognitive dysfunction and reward responsivity in schizophrenia</p> <p>\$46,000 direct costs</p> <p>The major aims of this project were to examine the affects of single dose nAChR partial agonist and antagonist on attention, reward responsivity, and working memory in non-smokers with and without schizophrenia. This foundation grant served as a supplement that allowed addition of a varenicline arm to a study of varenicline and placebo.</p>
2008 – 2010	NIDA R21 DA025186	PI	<p>Cutting Edge Basic Research Award: Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence</p> <p>\$200,900 total direct costs</p> <p>The major aim of this randomized clinical trial was to test the hypothesis that a single dose of propranolol given prior to smoking-related cue exposure would decrease psychophysiological responses to smoking cues one week later through a process of memory reconsolidation blockade.</p>
2006 – 2012	NIDA R01 DA022276	PI	<p>Glycine Transport Inhibition for Nicotine Dependence in Schizophrenia.</p> <p>\$727,715 total direct costs</p> <p>The major aim of this randomized controlled trial was to assessed the therapeutic potential of the glycine reuptake inhibitor, sarcosine, for negative</p>



			<p>symptoms, reward responsiveness and smoking cessation in individuals with schizophrenia. This study also evaluated associations between changes in negative symptoms, cognitive function, reward responsivity and brain glycine concentration with magnetic resonance spectroscopy.</p>
2004 – 2013	NIDA U01 DA019378	Co-PI and Project Director for Clinical Trial (Fava)	<p>Cooperative Drug Discovery for the Treatment of Nicotine Dependence</p> <p>\$1,804,546 total direct costs</p> <p>The major aim of this study was to test two novel Phase II compounds for efficacy for treatment of nicotine dependence and to test a predictive battery of putative biomarkers for response to treatment.</p>
2010 – 2013	NIDA R21 DA030808	PI	<p>Cognitive Remediation with D-cycloserine to Improve Smoking Cessation Outcomes</p> <p>\$289,776 total direct costs</p> <p>The major aim of this randomized clinical trial was to evaluate the effect of addition of the putative cognitive enhancing agent, D-cycloserine, to cue exposure therapy on reactivity to smoking related cues and relapse in recently abstinent smokers.</p>
2007 – 2013	NIDA R01 DA021245	PI	<p>Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia</p> <p>\$1,976,473 total direct costs</p> <p>The major aim of this randomized treatment discontinuation trial was to test the hypothesis that smokers with schizophrenia require extended duration pharmacotherapy to prevent relapse to smoking.</p>
2010 - 2014	Investigator Initiated Grant Pfizer Inc.	PI	<p>Extended duration varenicline for prevention of relapse to smoking in patients with schizophrenia</p> <p>\$229,060 total direct costs</p> <p>This investigator initiated study provides study medication and additional funding to supplement NIDA R01 DA021245 'Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia' to evaluate safety and efficacy of varenicline in smokers with schizophrenia</p>

2013 - 2014	Radcliff Institute for Advanced Study Conference Grant	PI	<p>Optimizing real time fMRI for neurotherapeutic discovery and development</p> <p>\$17,805 total direct costs</p> <p>This grant provided funding to hold an Exploratory Seminar at the Radcliffe Institute for Advanced Study to bring 18 scientists together from across the US for a two day meeting with the aim of advancing development of real time fMRI as a neurotherapeutic tool with applications to addictive disorders, obsessive compulsive disorder, major depressive disorder, post traumatic stress disorder and optimized learning.</p>
2011 – 2014	NIDA R21 DA030523	PI	<p>Enhancing Self-Control of Cigarette Craving with Real-Time fMRI</p> <p>\$376,916 total direct costs</p> <p>The major aim of this project is to develop, optimize, and test real time functional magnetic resonance imaging neurofeedback from specified brain regions active during inhibitory control on learned control of brain activation while viewing smoking-related cues.</p>

### Current Funded Projects

2010 – 2015	NIDA K24 DA030443	PI	<p>Mentoring in Addiction Treatment Research</p> <p>\$947,775 total direct costs</p> <p>The major aim of this career award is to provide support for mentoring of research fellows and junior faculty and to support training for the PI in genetics and neuroimaging techniques that will enhance clinical trials of nicotine dependence treatment interventions.</p>
2011 – 2016	NIDA R01 DA030992	<p>PI</p> <p>Joint PI: Fava</p>	<p>Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence</p> <p>\$2,784,741 total direct costs</p> <p>The aim of this project is to conduct a Phase IIb, randomized clinical trial to evaluate the effect of an alpha-7 nicotinic cholinergic receptor partial agonist</p>

			on cognitive deficits associated with nicotine withdrawal and assess its efficacy as a smoking cessation treatment when used as monotherapy or in conjunction with nicotine patch in a 2x2 design clinical trial.
2012 - 2017	Envivo Pharmaceuticals	PI  Joint PI: Fava	This investigator-initiated study provides study medication and additional funding to supplement NIDA R01 DA030992 to evaluate the efficacy of a novel alpha-7 nicotinic cholinergic receptor partial agonist for reducing cognitive deficits associated with nicotine withdrawal and assess its efficacy as a smoking cessation treatment.  \$280,000 total direct costs
2012 – 2015	NIDA R21 DA031925	MGH Site PI  PI: Kauf- man McLean	Concurrent PET D2/D3 receptor imaging and fMRI cue reactivity in smokers  \$141,238 total direct costs  This study aims to determine whether smokers have increased expression of dopamine D2/D3 receptors than do non-smokers and whether there is an association between D2/D3 expression, as measured with positron emission tomography, and functional MRI reactivity to smoking cues, which, when increased, predicts relapse to smoking after initial abstinence.
2013 - 2018	P50 DA 036107-01	PI  Multiple PI: Foulds Penn State	Project 2: Reduced Nicotine Cigarettes in Smokers with Mood and Anxiety Disorders  \$1,065,578 total direct costs  The major aim of this project is to evaluate the effect of progressive nicotine reduction in cigarettes on smoking behavior, toxin exposure and psychiatric symptoms in smokers with mood and/or anxiety disorders
2013-2017	NHLBI R01 HL112299	Co I and MGH Site PI  PI:	Comprehensive CVD Risk Reduction Trial in Persons with Serious Mental Illness (Triumph Trial)  \$50,634 total direct costs to MGH  The major aim of this trial is to test feasibility and

		Daumit Hopkins	effectiveness of an 18-month, comprehensive cardiovascular health intervention with a heart health specialist in a psychiatric rehabilitation setting in people with serious mental illness and cardiovascular risk factors with the major aim of reducing cardiovascular risk in this vulnerable population.
2013 - 2015	Global Foundation for Eating Disorders	PI	Neurobehavioral predictors of weight loss surgery outcomes  \$35,000 total costs  The major aim of this project is to begin to characterize neurobehavioral similarities and differences in certain phenotypes of obesity and addictive substance use disorders.
2014 - 2015	Private funding	PI	Longitudinal study of neurocognitive effects of cannabis use  \$20,000 total costs

**Current Unfunded Projects**

2014 - 2019	NIMH R01 MH104553	PI  Multiple PI: Daumit Hopkins	Trial of Integrated Smoking Cessation, Exercise, and Weight Management in SMI (Achieve Trial)  2,286,536 total direct costs  Nicotine addiction is an entrenched problem for half of adults with serious mental illness, most of whom want to quit smoking, but rates of guideline-concordant cessation treatment are minimal. We propose a randomized trial embedded in community mental health programs to test a practical smoking cessation program integrating weight management counseling, exercise and text messaging support. If successful, the intervention will be a model program that could be disseminated widely and should reduce health disparities in cardiovascular disease risk in persons with serious mental illness.  In line for funding, awaiting NGA.
-------------	-------------------	--	--

2014 - 2018	NIMH R01 MH104560	Co-I	Fixed dose intervention trial of New England enhancing survival in SMI patients (FITNESS)
		PI:	
		Ongur	\$3,553,182 total costs
		McLean	
			<p>This project proposes to conduct an open-label, four-site randomized controlled trial of a fixed-dose, combination of drugs versus usual treatment for the prevention of cardiovascular disease among patients receiving second-generation antipsychotic drugs for severe mental illness. The trial assesses the effectiveness of an initial treatment strategy using moderate doses of HMG-Co A reductase inhibitors and angiotensin receptor blockers which have proven efficacy and safety. We will test this treatment strategy within mental health clinics.</p>
			In line for funding, awaiting NGA.
2014 - 2017	NIDA R01 DA037372	PI	E-cigarette acceptability, use and effects in smokers with schizophrenia
		Multiple	
		PI Tidey	\$956,988 total direct costs
		Brown	
			<p>This project will investigate the effects of 6-week e-cig distribution on concurrent and subsequent nicotine and toxicant intake, cigarette use, smoking topography and psychiatric symptoms in smokers with schizophrenia and control smokers sampled from the general population.  Priority score: 19, 4<sup>th</sup> percentile. Not funded.  Collecting preliminary data to support a revised application.</p>

## Report of Local Teaching and Training

### Teaching of Students in Courses

1996 - 2006	Novel Antipsychotic Agents; Psychosis Seminar Lecturer PGY-3 Residents	Massachusetts General Hospital Three one-hour lectures per year
1998 - 2001	Treatment of Schizoaffective Disorder Bipolar Disorder Seminar Lecturer MGH PGY-3 Residents	Massachusetts General Hospital Three one-hour lectures per year
1999 - 2009	Antipsychotic Medications: Adverse Effects; MGH Psychopharmacology Lecture PGY-2 Residents	Massachusetts General Hospital Three one-hour lectures per year
2000 - 2006	Nicotine and Smoking Cessation in Schizophrenia. Harvard Clinical Addiction Fellowship Lecture Series Post Doctoral Fellows	Massachusetts General Hospital One three-hour lecture/seminar per year
2004 - 2011	Neurobiology of Addiction, Acute Psychiatry Service Lecture Series PGY-2 Psychiatry Residents	Massachusetts General Hospital Three one-hour lectures per year
2003 - 2005 2010 - 2012	Undergraduate Neurobiology Thesis Advisor One undergraduate student per period	Harvard University Department of Psychology Three hours per week for 9 months per year
2005 - 2006	Substance Use and Dependence and Co-occurring Major Psychiatric Illness Lecturer for Psychiatry 700 course Second Year Medical Students	Harvard Medical School Department of Psychology One one-hour lecture per year
2007 - 2011	Examiner: Medical Student Comprehensive Exam Fourth Year Medical Student	Harvard Medical School One four-hour session per year
2007 - present	Therapeutic Strategies for Nicotine Dependence Treatment PGY3 Psychiatry Residents	Massachusetts General Hospital Three one-hour lectures per year
2007 - 2011	Negative Symptoms in Schizophrenia: Neurobiology and Treatment. Seminar Lecturer MGH PGY-3 Residents	Massachusetts General Hospital Three one-hour lectures per year
2013 - present	Neurobiology of Addiction Behavioral Neurology and Neuropsychiatry Fellowship Program	Massachusetts General Hospital One one-hour lecture per year

## **Formally Supervised Trainees**

- 2003 - 2005 Erica Cowman, MD  
Harvard College Honors Undergraduate Psychology Thesis Advisor:  
The effects of a D2/D3 agonist, pramipexole, on reward responsivity in normal adults.  
Thesis Awarded High Honors. Department of Psychology, Harvard University.  
Current Position: PGY-3 Resident in Radiology University of Washington School of  
Medicine
- 2004 - 2007 Ruth S. Barr, MB BCH  
Primary Doctoral Thesis Supervisor: Effects of nicotine on cognition and reward  
sensitivity in schizophrenia. Doctoral Degree awarded Queens University, Belfast,  
UK. 2005  
7 papers co-authored  
Current Position: Psychiatrist Belfast Ireland
- 2005 Tom Melicher, MD  
Medical Student, Prague, Czech Republic  
Mentor for Visiting Research Internship  
Current Position: Psychiatrist, Researcher, Prague Psychiatric Center
- 2005 - 2006 Karsten Kueppenbender, MD  
Clinical Addiction Psychiatry Fellow  
Current Position: Instructor in Psychiatry, Harvard Medical School, Associate Medical  
Director, MGH West End Clinic
- 2005 - 2006 Lindsay Jubelt, MD  
2005 Harvard-Pasteur Doris Duke Clinical Research Fellowship, Mentor.  
2 papers co-authored  
Current Position: Instructor-Department of Population Health NYU Medical Center
- 2005 - 2008 Tsafir Loeb, MD  
Primary Mentor: NIDA International Program.  
3 papers co-authored  
Current position: Senior Psychiatrist Hadassah Medical Center, Israel
- 2006 - 2007 Rocco Iannucci, MD  
Clinical Addiction Psychiatry Fellow  
Current Position: Instructor in Psychiatry, HMS, practicing addiction psychiatrist,  
Boston, MA
- 2006 - 2008 Catherine Fullerton, MD  
Primary Mentor NARSAD Young Investigator Award.  
Mecamylamine probe of role of nicotinic acetylcholine receptors in cognition in  
schizophrenia.  
1 paper co-authored  
Current Position: Practicing psychiatrist, Boston, MA

2006 - 2008 Andrew Prescott, PhD  
Mentor and Site Principal Investigator, NARSAD Young Investigator Award.  
1 paper co-authored  
Current position: Assistant Professor of Radiology, University of Utah School of  
Medicine

2006 - 2008 Janet Witte, MD  
Mentor, NARSAD Young Investigator Award.  
1 paper co-authored  
Current position: Instructor in Psychiatry, HMS, Practicing psychiatrist, Boston, MA

2007 - 2008 Stuart Wallace  
Masters Thesis, Advisor, Tufts University

2007 - 2008 Abigail Schein, MD,  
Clinical Psychiatry Research Fellow  
Current position: Practicing psychiatrist VA Healthcare System, Boston, MA

2008 Rebecca McEvelly, Medical Student, University of Toronto, Toronto, Canada  
Summer internship with Dr. Evins as Mentor

2008 - 2010 Carl Anderson, PhD  
Primary Mentor NARSAD Young Investigator Award.  
Current position: Assistant Psychobiologist at the McLean Hospital Developmental  
Biopsychiatry Research Program

2008 - present Gladys N. Pachas, MD  
2008 – 2010 Research Fellowship, Primary Mentor  
2010 NCDEU New Investigator Award, Primary Mentor  
2011 National Institute on Drug Abuse Interdisciplinary Research Training  
Institute Fellow and Travel Awardee, Sponsor  
2012 American Society of Clinical Psychopharmacology Fellow and Travel  
Awardee  
2014 Society for Research on Nicotine and Tobacco: Increasing diversity in  
Nicotine and Tobacco Research Travel Scholarship to the 2014 SRNT  
Annual Meeting  
9 papers and 1 chapter co-authored  
Current position: Instructor in Psychiatry, Harvard Medical School

2008 - 2010 Johanna Nino, MD  
Research Fellowship Advisor/Primary Mentor  
4 papers co-authored  
Current position: PGY-4 Adult psychiatry resident, and physician in the Center for  
Psychopharmacologic Research and Treatment, University of  
Massachusetts Medical School, Worcester MA



- 2009 - 2011 Kimberly Lindsey, PhD  
Primary Mentor, NARSAD Young Investigator Award.  
Current position: Instructor in Psychiatry McLean Hospital, Brain Imaging Center
- 2009 - 2013 Zev Schuman-Olivier, MD, PhD  
Half time research fellow, MGH Center for Addiction Medicine & Half time Clinical  
Addiction Psychiatry Fellow, HMS  
2010 - 2012 NIDA Loan Repayment Program Grant, NIDA NYRL6185: Mindful  
Neuromodulation: Development of mindfulness-based real time-fMRI  
neurofeedback for smoking cessation; Primary Mentor  
2010 - 2012 Mind & Life Institute Francisco J. Varela Research Award: Neural  
Correlates of Mindfulness Medication in Adults with Nicotine  
Dependence; Primary Mentor  
2011 Harvard Medical School Dupont-Warren Fellowship Award; Primary  
Mentor  
2012 American Academy of Addiction Psychiatry Young Investigator Award  
1 paper and 1 chapter co-authored, other papers and abstracts in preparation  
Current position: Medical Director Westbridge Family Centered Treatment Program  
for Mental Illness and Substance Use Disorders Boston Area Team
- 2009 - present Luke Stoeckel, PhD  
2009 - 2012 Research Fellow, MGH Center for Addiction Medicine  
2010 - 2011 Harvard Medical School Zinberg Fellowship in Clinical Addiction  
Research: Development of Real-Time fMRI as a Novel Adjunctive  
Behavioral Treatment for Addictions, Primary Mentor.  
2011 Harvard Medical School Department of Psychiatry Mysell Award for work  
completed during the Zinberg Fellowship  
2010 - 2013 NIDA Loan Repayment Program Grant, Primary Mentor  
2011 - 2013 NARSAD Young Investigator Award, Primary Mentor  
2011 NCDEU New Investigator Award  
2012 Promoted to Instructor then Assistant Professor, Harvard Medical School  
2012 - 2017 K23 DA 032612 Training in Neurobehavioral Addiction Research,  
Primary Mentor  
2012 - 2014 Awarded the Charles A. King Trust Postdoctoral Fellowship  
2013 – 2015 Global Foundation for Eating Disorders grant awarded, Dr. Evins as  
mentor  
2013 ACNP Travel Award  
3 papers and 1 chapter co-authored, other papers and abstracts in preparation, 1  
undergraduate honors thesis co-mentored  
Current Position: Director of Neuroscience at the NIH National Institute of Diabetes  
and Digestive and Kidney Diseases (NIDDK) Division of Diabetes,  
Endocrinology, & Metabolic Diseases
- 2010 - present Amy Janes, Ph.D.  
Junior faculty for training in clinical research, MGH Center for Addiction Medicine.  
2010 Harvard Mysell Award  
2011 - 2016 NIDA K01DA029645, Training in Cognitive Function and Neuroimaging  
of Smoking-Related Cues with Dr. Evins as mentor  
2013 ACNP Travel Award  
6 papers co-authored, R01 under review

Current position: Assistant Professor of Psychiatry, Harvard Medical School and  
Director, Functional Integration of Nicotine & Addiction Research  
Laboratory, McLean Hospital

- 2010 – 2012      Gustavo Angarita, M.D.  
Research fellow, MGH Center for Addiction Medicine  
Clinical Addiction Psychiatry Fellow, HMS  
1 paper co-authored  
Current position: Instructor in Psychiatry Yale University and Associate Inpatient  
Chief of the Clinical Neuroscience Research Unit (CNRU) at the  
Connecticut Mental Health Center
- 2011 – present      Paola Pedrelli, PhD  
2011 – 2016 K23 AA020064, Enhanced treatment for binge drinking in depressed  
college students with Dr. Evins as co-Mentor  
Current position: Instructor in Psychology, Harvard Medical School
- 2010 – 2012      Janani Raveendran  
Undergraduate thesis student, Harvard College, Department of Neurobiology  
With Dr. Evins as Thesis Advisor,  
Thesis entitled 'An fMRI study of visual cue-induced brain activation in nicotine-  
dependent smokers' awarded 'Honors'.  
2011-2012 Competitive Harvard College Research Program Fellowship Award  
Current position: Medical student, George Washington School of Medicine
- 2011 - 2014      Sungwon Roh, MD  
South Korean Government Fellowship in Clinical Research Methods, Primary Mentor  
2012      NCDEU New Investigator Award for the Poster entitled 'Cognitive effects  
of mecamylamine and varenicline in schizophrenia'  
2 papers co-authored  
Current Position: Director Department of Mental Health Research, National Center  
for Mental Health Research & Education, Seoul National Hospital, Korea
- 2011- present      Heidi J. Wehring, PharmD, University of Maryland  
2012 - 2017      NIDA K23 award awarded to examine nicotine craving in persons with  
schizophrenia, including triggers, cue responsivity, and emotion, and a pilot  
pharmacotherapy trial to reduce craving, Mentor and a member of her two person  
career advisory board  
Current position: Assistant Professor of Psychiatry, University of Maryland
- 2011      Sarah J. Leslie  
Master of Science Degree awarded from University of Amsterdam, Department of  
Clinical Psychology for work performed at MGH. 'Selective Processing of Smoking  
Cues in Smokers with Lifetime History of Major Depressive Disorder'
- 2011 - present      Travis Baggett, MD

2012 – 2017 NIDA K23 DA034008 awarded to study contingency management approaches to smoking cessation in homeless smokers, Co-mentor  
Current position: Instructor in Medicine, Harvard Medical School

- 2012 - present Jodi Gilman, PhD  
2012-2013 Harvard Zinberg Fellowship in Clinical Addiction Research Awarded, Primary Mentor  
2013-18 NIDA K01 awarded, Mentor  
2013 ACNP Travel Award  
2012-2013 NIDA Loan Repayment Grant Award  
1 co-authored paper, 1 co-authored paper under review  
Current position: Instructor in Psychiatry, Harvard Medical School
- 2012 - 2015 Lauren Moran, MD  
2012-13 NIDA Loan Repayment grant, Primary Mentor  
2013-14 Harvard Medical School Dupont-Warren Award and Livingston Award to conduct the study: Aberrant salience of smoking-related cues in schizophrenia, Primary Mentor  
2013-15 NARSAD Young Investigator Award, Mentor  
Current position: Instructor in Psychiatry Harvard Medical School and Psychiatrist in Charge, Schizophrenia and Bipolar Disorders Unit, McLean Hospital
- 2013 - present Clarissa Martinez-Rubio, PhD  
2013 NIDA K01 submitted, Mentor  
Current position: Instructor, Department of Neurosurgery, Harvard Medical School
- 2013 Regina van der Meer, MPH, Doctoral Candidate, University of Amsterdam  
European Graduate School in Addiction Research (ESADD) sponsored visiting research visit to MGH in March 2013, Mentor.  
Current position: Doctoral Candidate, Amsterdam Institute for Addiction Research, University of Amsterdam
- 2014 - present Randi Schuster, PhD  
Post doctoral fellow, MGH Center for Addiction Fellow, Dr. Evins as primary mentor.

**Formal Teaching of Peers (e.g., CME and other continuing education courses)**

**Local**

2005, 2006	Reduction of Cardiac Risk in Patients with Major Mental Illness through Smoking Cessation and Weight Management	Harvard Medical School Psychopharmacology Continuing Medical Education Course	Boston, MA
2005, 2007	Inositol for Panic, OCD, and Depression	MGH Natural Remedies Continuing Medical Education Course	Boston, MA
2005	Between a Clinical Rock and a Hard Place: Treating Anxiety in the Substance Abusing Patient	MGH Psychiatry Academy PsychLink Broadcast Content Development and Faculty	Dallas, TX
2005	Managing the Side Effects of Antipsychotic Drugs	MGH Psychiatry Academy Continuing Medical Education Course	Washington, D.C.
2005	Management of Metabolic Adverse Events Associated with Antipsychotic Treatment.	MGH Psychiatry Academy Continuing Medical Education Course	Atlanta, GA Washington, D.C.
2005	Reducing Cardiac Risk in Patients with Major Mental Illness: Smoking Cessation and Weight Control	MGH Psychiatry Academy, Live Symposium Continuing Medical Education Course	Atlanta, GA
2006 - present	Neurobiology of Addiction	Harvard Medical School Psychopharmacology Continuing Medical Education Course	Boston, MA
2006 - present	Treatment of Substance Use Disorders II	Harvard Medical School Psychopharmacology Continuing Medical Education Course	Boston, MA
2006	Treatment for Nicotine Dependence in the Setting of Co-Occurring Depressive or Psychotic Disorder	MGH Psychiatry Academy Live Symposia Content development and faculty	Nine cities in the US
2007	Management of Alcohol Dependence: Lessons Learned from the COMBINE Study	MGH Psychiatry Academy PsychLink Broadcast	Boston, MA
2007	Advances in Treatment of Alcohol, Nicotine and Opiate Dependence	MGH Psychiatry Academy Live Symposium. Content Development and Faculty for lectures	Six cities in the US

2011	Tobacco Smoking in Patients with Psychiatric Illness	Addictions in 2011 Conference: Harvard Medical School and McLean Hospital. Physicians, Nurses, Social Workers, Physician Assistants, Addiction Counselors	Boston, MA
2012	Addiction Neurobiology: What We Have Learned from Neuroimaging	The State of Psychiatry. A CME Course for Psychiatrists in the U.S. State Department	Boston, MA

**Regional**

2007	The Brain/Addiction Connection: Understanding Substance Abuse in Adolescents and Young Adults	North Shore Medical Center Physicians, other medical professionals	Danvers, MA
------	---	---	-------------

**National**

2008	Psychopharmacologic Treatment of Addictive Disorders	Mt Sinai School of Medicine. Physicians, Residents, Fellows	NY, NY
2012	Varenicline, Where are we today?	Tobacco Related Disease Research Program University of California, Office of the President	San Francisco, CA
2013	Neurobiology of Tobacco Addiction	5th Annual C. Everett Koop, MD Tobacco Treatment Conference, Dartmouth College	Fairlee, VT

**Report of Local, Regional, National and International Invited Teaching Presentations**

**Local Invited Presentations**

1998	Acute Management of Psychosis	Summer Crash Course. Harvard Longwood Psychiatry Residency Training Program, Massachusetts Mental Health Center: PGY-2 residents	Boston, MA
1998	Novel Antipsychotic Agents	Erich Lindemann Mental Health Center Psychology Training Seminar: Attending psychiatrists, resident psychiatrists, and pre-doctoral psychology interns	Boston, MA
2000	Novel Antipsychotic and	Beth Israel-Deaconess Ward Teaching	Boston, MA

	Anti-epileptic Therapies in Bipolar Disorder	Rounds-Deaconess 4: Psychiatry staff and PGY-2 residents, nursing, social work, and occupational therapy staff and trainees	
2000	Nicotine, Nicotinic Receptors and Schizophrenia	McLean Hospital Psychopharmacology Grand Rounds: Psychiatry Staff, Residents, Fellows and Nursing Staff	Belmont, MA
2001	Nicotine and Cholinergic Systems: Relevance for Cognitive Dysfunction in Schizophrenia	Massachusetts Mental Health Center Psychopharmacology Grand Rounds	Boston, MA
2003	Nicotine, Smoking, and Schizophrenia	Grand Rounds Cambridge Hospital Department of Psychiatry	Cambridge, MA
2003	A 54-year-old woman with cough. Discussion of smoking cessation treatments and hurdles in patients with psychotic disorders	MGH Clinical Pathologic Conference	Boston, MA
2005	MGH PGY-IV Resident Psychosomatics Conference	Massachusetts General Hospital; Faculty Advisor for C. Fullerton, MD	Boston, MA
2005	MGH PGY-IV Resident Psychosomatics Conference	Massachusetts General Hospital; Faculty Advisor for R. Iannucci, MD	Boston, MA
2005	MGH PGY-IV Resident Psychosomatics Conference	Massachusetts General Hospital; Faculty Advisor for J. Witte, MD	Boston, MA
2007	Smoking Cessation in Schizophrenia	Psychopharmacology Grand Rounds, Cambridge Hospital Department of Psychiatry	Cambridge, MA
2007	Nicotine Dependence Treatment in the Setting of Other Addiction Treatment	West End Clinic Staff Rounds. Massachusetts General Hospital	Boston, MA
2008	Neurobiology of Addiction for Clinicians	MGH Perinatal Addiction Conference. Massachusetts General Hospital. Physicians, Nurses, Social Workers.	Boston, MA
2008-2011	Behavioral and Pharmacologic Treatment for Nicotine Dependence	Cambridge Hospital Department of Psychiatry, PGYI and PGY IV Residents	Cambridge, MA
2011	Neurobiology of Addiction: Reward and Inhibitory Control Abnormalities	Psychiatric Genetics and Translational Research Seminar, Residents, Post Doctoral Fellows and Faculty, Simches Research Center, MGH	Boston, MA
2011	Neurobiology of Addiction, Just Say No?	Massachusetts General Hospital Combined Neuroscience Grand Rounds	Boston, MA

		Neurology, Neurosurgery, Psychiatry and Neuroscience Faculty, MGH	
2012	Neurobiological Basis of Addiction	Harvard School of Public Health Substance Abuse and Public Health Course	Boston, MA
2012	Emerging understanding of the neurobiology of addiction	United States Department of State Psychiatric Educational Symposium	Boston, MA
2012 - 2014	Preceptor at Partners K Award Workshop Three programs per year for early career investigators applying for K23 career awards and for mid-career investigators applying for K24 awards	Sponsored by the MGH Clinical Research Program One to two 3-hour seminars per year	Boston, MA
2012	Nicotine dependence treatment In smokers with mental illness: Toward best practices	MGH Psychiatry Academy Webcast	Boston, MA
2013	Symposium 4: Prochaska vs. Singh Debate: Does Varenicline increase Cardiovascular Adverse Events: Moderator	Society for Research on Nicotine and Tobacco 19 <sup>th</sup> Annual International Meeting	Boston, MA
2013	Extended Duration Pharmacotherapy Reduces Relapse to Smoking in Schizophrenia and Bipolar Disorder	Society for Research on Nicotine and Tobacco 19 <sup>th</sup> Annual International Meeting Symposium 12: $\alpha 4\beta 2$ -Nicotinic acetylcholine receptors in schizophrenia: implications for comorbid tobacco smoking and therapeutics	Boston, MA

### **Regional Invited Presentations**

1997	Assessment and Treatment of Psychosis in an Emergency Setting	Boston Emergency Services Team Training Seminar. Psychiatrist, Nursing and Social work staff and mental health workers	Boston, MA
1998	Nicotine and Smoking in Schizophrenia	Psychiatric Grand Rounds Medfield State Hospital: Medical, nursing, and social work staff	Medfield, MA

1998	Nicotine and Smoking in Schizophrenia	North Suffolk Mental Health Association Clinical Staff Rounds Lecturer: Psychology and social work staff	Boston, MA
2000	Smoking Cessation Treatments in Schizophrenia: Efficacy with Symptom Stability	MIT Health Services Psychopharmacology Grand Rounds: Psychiatry and Psychology staff	Cambridge, MA
2001	Assessment and Treatment of Schizophrenia Prior to Tobacco Treatment.	Massachusetts Department of Public Health and University of Massachusetts Medical Center Tobacco Treatment Specialist Training: Psychiatry residents, nurses, social workers, addiction counselor	Boston, MA
2001	Antipsychotic Medications in Bipolar and Schizoaffective Disorders and Substance Use Disorders	Bournewood Hospital Grand Rounds: Psychiatry, nursing, and social work staff	Chestnut Hill, MA
2001	Nicotine and Smoking Cessation in Schizophrenia	Massachusetts Department of Mental Health, Health and Wellness Conference	Boston, MA
2001	Smoking Cessation Therapies	Psychopharmacology Grand Rounds, Bedford VA Hospital	Bedford, MA
2002	Assessment and Treatment of Schizophrenia Prior to Tobacco Treatment	University of Massachusetts Medical Center Tobacco Treatment Specialist Training: Tobacco Treatment Specialists, nurses, social workers, addiction counselors	Worcester, MA
2002	Assessment and Treatment of Psychiatric Symptoms Prior to Tobacco Treatment	Massachusetts Department of Public Health and University of Massachusetts Medical Center Tobacco Treatment Specialist Training: Psychiatry residents, nurses, social workers, and addiction counselors.	Boston, MA
2002	Nicotine, Nicotinic Receptors and Schizophrenia	Tufts New England Medical Center Psychiatry Grand Rounds. Psychiatry, nursing and social work staff	Boston, MA
2003	Clinical Concepts for the Courtroom: A Program for Judges	Massachusetts Continuing Legal Education Inc. Psychiatric Disorders	Boston, MA
2004	20 Years since Rogers: Mental Health Medications and the Law Today: Benzodiazepines	Mental Health Legal Advisors Committee. Lawyers.	Boston, MA



2004	Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment	University of Massachusetts Medical Center Psychopharmacology Grand Rounds: Psychiatric residents and staff	Worcester, MA
2004	Safe Conversion to Smoke-Free Inpatient Psychiatric Units	Massachusetts Hospital Association Behavioral Health Meeting (Massachusetts Medical Society, Hospital administrators and staff.	Boston, MA
2006	Nicotine and Schizophrenia: Smoking Cessation and Cognitive Enhancement	Grand Rounds Boston Medical Center. DMH administrators, physicians, psychiatry residents, nurses, social workers, addiction counselors.	Boston, MA
2006	Nicotine and Schizophrenia: Smoking Cessation and Cognitive Enhancement	Grand Rounds Westboro State Hospital. DMH administrators, physicians, psychiatry residents, nurses, social workers, addiction counselors.	Westboro, MA
2006	Smoking Cessation Treatment in Schizophrenia	Veterans Administration Medical Center. Physicians, psychiatry residents, nurses, social workers, addiction counselors	Northampton, MA
2007	Nicotine, Reward, and Schizophrenia	Psychiatry Rounds, Boston VA Hospital, Psychiatrists and Psychologists	Jamaica Plain, MA
2007	The Brain Addiction Connection	Partners Addiction Conference, Pediatricians, Psychiatrists, Family Practice Physicians and Nurses, Partners Healthcare	Boston, MA
2011	The Neurobiology of Addiction, Just Say No?	Invited Speaker, The Roxbury Society for Medical Improvement	Boston, MA
2012	Effective Smoking Cessation Treatments for Those with Mental Illness: Why Smoking Cessation Treatment Must be Offered in Behavioral Health Settings	Presentation to Planning Group Convened by Tobacco Free Mass Funded by a NIH grant to the American Lung Association	Framingham, MA
2013	Meeting the challenge: Toward 'Best Practices' in treating nicotine dependence in those with major depressive disorder and schizophrenia	Department of Psychiatry Grand Rounds Presentation Boston Veterans Administration Hospital System	Boston, MA

## National Invited Presentations

2000	Nicotine and Smoking Cessation in Schizophrenia	National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD) Annual Meeting	New York, NY
2001	Treatments That Target Both Psychiatric Symptoms and Nicotine Addiction	American Association of Addiction Psychiatry Annual Meeting	Amelia Island, FL
2002	Tobacco Related Health Disparities in People with Major Mental Illness	National Institutes of Health and National Cancer Institute: Tobacco Related Health Disparities Colloquium	Tampa, FL
2007	Glutamatergic Dysfunction in Schizophrenia: Implications for Nicotine Dependence and Negative Symptoms	Grand Rounds University of Maryland and Maryland Psychiatric Research Center	Baltimore, MD
2007	Reward Responsivity and Negative Symptoms: A Novel Tool for Clinical Trials	Symposium at the American College of Neuropsychopharmacology 46 <sup>th</sup> Annual Meeting	Boca Raton, FL
2007	A Single Dose of Nicotine Enhances Reward Responsivity in Non-smokers: Implications for Development of Dependence	American College of Neuropsychopharmacology 46 <sup>th</sup> Annual Meeting Invited seminar: <i>Hot Topics</i>	Boca Raton, FL
2008	Clinical Imperatives: Nicotine Dependence Treatment and Long Term Abstinence for Smokers with Schizophrenia	National Alliance for the Mentally Ill Annual Conference	Orlando, FL
2008	Update on Antipsychotics: Treatment of Patients with Schizophrenia Spectrum Disorders	Center for Continuing Education in the Health Sciences at Dartmouth College and Dartmouth-Hitchcock Medical Center	Hanover, NH
2009	Current Strategies for Smoking Cessation Treatment and Prevention of Smoking-Related Eye Disease	Seminar: Reducing Sex and Gender Disparities in Eye Disease and Treatment" Association of Vision and Ophthalmology (ARVO) Annual Meeting	Ft. Lauderdale, FL
2009	Psychiatric Co-Morbidities In Smokers: Implications for Nicotine Dependence Treatment	Invited Seminar. National Conference on Tobacco or Health	Phoenix, AZ

2009	Pharmacotherapies with Proven Clinical Efficacy for Validation of Screening Tools for Medications Discovery	NIDA Invited Speaker: Validation of in vivo screening for Drug Discovery and Development: Focus on Smoking Cessation	Rockville, MD
2009	Efficacy of Varenicline and Bupropion for Nicotine Dependence in Schizophrenia: Implications for Treatment of Other Substance Use Disorders in Schizophrenia	NIAAA (R13) Sponsored Conference on Pathophysiology and Treatment of Comorbid Psychiatric and Substance Use Disorders. Sponsored by Dartmouth Medical School	Fairlee, VT
2009	Improving treatment outcomes using a personalized medicine approach, examples from nicotine dependence research and treatment	Symposium at the American College of Neuropsychopharmacology 48 <sup>th</sup> Annual Meeting	Hollywood, FL
2012	Transitioning to Translational Medicine: Translating pre-clinical findings into clinical applications	Moderator, Discussion Group at the Society for Research on Nicotine and Tobacco 18 <sup>th</sup> Annual Meeting	Houston, TX
2012	Psychiatric Comorbidities Associated with Varenicline	Panelist Presentation to the UCSF Tobacco Related Disease Research Program	San Francisco, CA
2012	Cognitive Enhancement and Remediation Strategies to Improve Smoking Cessation Outcomes	2012 APA Symposium: Neurobehavioral and Pharmacological Approaches to Target Cognitive Remediation in Drug Addiction	Philadelphia PA
2012	Enhancing Self-Control of Neural Activation Subservicing Tobacco Craving with Real Time Neurofeedback	Invited Speaker, Duke Nicotine Conference	Durham, NC
2012	Cognitive Remediation with D-cycloserine Added to Cue Exposure Therapy in Recently Abstinent Smokers	Invited Speaker, Panel entitled: Behavioral Paradigms to Improve Signal Detection in Trials of Cognition Enhancing Drugs Annual Meeting of the American College of Neuropsychopharmacology	Hollywood, FL
2013	Varenicline, NRT and bupropion for smoking cessation in schizophrenia	Invited speaker: NIDA, NIMH, NCI sponsored workgroup to identify knowledge gaps and research opportunities with regard to research on smoking cessation in people with	Rockville, MD

schizophrenia

2013	Extended Duration Pharmacotherapy for Sustained Tobacco Abstinence in People with Serious Mental Illness	Panel Chair and Speaker $\alpha 4\beta 2$ -Nicotinic Acetylcholine Receptors in Schizophrenia: Implications for Smoking Cessation and Therapeutics. Annual Meeting of the American College of Neuropsychopharmacology	Hollywood, FL
2014	Maintenance Varenicline for Prolonged Abstinence in Smokers with Schizophrenia and Bipolar Disorder	Special Invitation by the NIDA Division of Pharmacotherapies and Medical Consequences of Drug Abuse to Present Grand Rounds	Rockville, MD
2014	Mental Illness and Smoking Cessation	Chair of Paper Session: Mental Illness and Smoking Cessation. 20 <sup>th</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco	Seattle, WA
2014	Bridging the Gap Between Preclinical and Clinical Findings: Forward and Reverse Translation	Invited Discussant, Transdisciplinary Topical Discussion. 20 <sup>th</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco	Seattle, WA
2014	Serious Mental Illness and Smoking Cessation Treatment	Plenary Speaker Annual Pittsburgh Schizophrenia Conference	Pittsburgh, PA
2014	Proponents and Opponents of Legalization of Marijuana: Evidence of Benefits and Costs in Three Areas: Psychosis, Cognition, and Motivation	Speaker in an Invited Study Group Organized by NIDA to be held at the 2014 annual meeting of the American College of Neuropsychopharmacology	Phoenix, AZ

### **International Invited Presentations**

2005	Predictors of Smoking Cessation in Patients with Schizophrenia	Presentation 11 <sup>th</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco	Prague, Czech Republic
2007	Mental Health, Smoking, Smoking Cessation and Going Smoke Free	Plenary Presentation United Kingdom National Smoking Cessation Conference	London, UK
2007	The Future of the NHS Smoking Cessation Services	United Kingdom National Smoking Cessation Conference	London, UK
2008	Shared Vulnerability to Nicotine and other	NIDA Sponsored Symposium: Smoking Cessation in the Practice of	Toronto, Canada

	Addictive Disorders	Addiction Medicine at the 39 <sup>th</sup> Annual Medical Scientific Conference of the American Society of Addiction Medicine	
2008	Schizophrenia and Nicotine Use: Effects on Cognition and Therapeutic Implications.	Society for Research on Nicotine and Tobacco	Rome, Italy
2009	Nicotinic Receptor Abnormalities in Schizophrenia and How These Can Inform Novel Nicotine Dependence Treatment Development	Invited NIDA-Sponsored Symposium: World Conference on Tobacco or Health "Smoking and Co-Morbid Diseases"	Mumbai, India
2009	Effects of Nicotine on Reward Responsiveness and Cognitive Performance in Non-smokers with and without Schizophrenia	Invited Symposium 15 <sup>th</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco and Joint Conference with SRNT Europe	Dublin, Ireland
2009	Safety of Varenicline in Schizophrenia	Invited Talk, <i>Hot Topics</i> Paper Session. 15 <sup>th</sup> Annual Meeting of the Society for Research on Nicotine and Tobacco and Joint Conference with SRNT Europe	Dublin, Ireland
2010	Pathways to Reduce Human Health Hazards Caused by Tobacco	Keynote Speaker 8 <sup>th</sup> Annual Conference of the International Society for the Prevention of Tobacco Induced Diseases	Boston, MA
2012	Toward 'Best Practices' in treating nicotine dependence in those with major mental illness	Plenary Clinical Theme Lecture, European Society for Research on Nicotine and Tobacco	Helsinki, Finland

## **Report of Clinical Activities and Innovations**

### **Current Licensure and Certification**

07/91 - 06/92	Limited Medical License	Children's National Medical Center, Washington, D.C.	State of Maryland
07/92 - 06/95	Limited Medical License	Massachusetts Mental Health Center	Commonwealth of Massachusetts
07/95 - Present	Full Medical License	Massachusetts General Hospital	Commonwealth of Massachusetts

1995 - Present	Diplomate, American Board of Psychiatry and Neurology	
1995 - Present	Controlled Substances Practitioner	Commonwealth of Massachusetts
2011- Present	Prescribing License for Buprenorphine ('X License')	Federal DEA

**Practice Activities**

1995 - 2001	Clinical work, 20 hours per week	MGH Schizophrenia Program at the Freedom Trail Clinic of the Eric Lindemann Mental Health Center
2001 - 2011	Clinical consultations, 10 - 15 hours per week	MGH Schizophrenia Program at the Freedom Trail Clinic of the Eric Lindemann Mental Health Center
1998 - 2001	Outpatient clinical care, 8 - 10 hours per week	MGH Bipolar Disorder Program and Clinic
2005 - Present	Clinical consultations, 1 - 2 hours per week	MGH Center for Addiction Medicine

**Clinical Innovations**

Schizophrenia Tobacco Treatment Program	Massachusetts General Hospital based at the Freedom Trail Clinic; The purpose of the program has been to implement nicotine dependence treatments for patients with schizophrenia at the Massachusetts General Hospital, Massachusetts Mental Health Center, Shattuck Hospital, and the South Boston Community Medication Clinic in Boston, and at the Community Health Link Clinic in Worcester, North Central Human Services in Gardner and Child and Family Services in New Bedford as well as to foster training of mental healthcare staff, primarily psychiatrists, nurses and social workers who work in community mental health centers in Massachusetts in nicotine dependence treatment.
Guidelines for Psychiatrists for Preventive Medical Management of Patients with Major Mental Illness	On Commonwealth of Massachusetts Department of Mental Health committee for development.
Guidelines for Management of Bipolar Disorder	On Commonwealth of Massachusetts Department of Mental Health committee for development.
Development of a smoking cessation treatment consortium	Served 5 community mental health centers in Massachusetts. Provided tobacco treatment specialist training to mental health clinicians at these sites in order to enable people with

experience treating people with major mental illness to be able to provide smoking cessation treatment for patients in their clinic. The impact of this was to initiate provision of smoking cessation treatment at mental health centers where it was not previously offered.

Treatment guidelines for smoking cessation for people with schizophrenia

Cochrane Review concluded beneficial effect of bupropion treatment with or without nicotine replacement therapy for smoking cessation in people with schizophrenia with good safety profile. NIMH-sponsored PORT guidelines for treatment of schizophrenia subsequently made the first clinical treatment recommendation for smoking cessation in schizophrenia based on this evidence.

### **Report of Education of Patients and Service to the Community**

- 1996 - Present      Speaker, National Alliance for the Mentally Ill (NAMI) and REFUAH, organizations for family members of people with major mental illness. Representative talks: Effective smoking cessation treatments and symptom management for smokers with mental illness. Novel treatments for bipolar disorder.
  
- 2001                      Systematic Treatment Enhancement Program for Bipolar Disorder  
Speaker for Manic Depression and Depression Association of Patients and Family Members
  
- 2004                      Cardiac Mortality and Smoking Cessation Strategies for People with Schizophrenia  
MGH Schizophrenia Education Day Lectures to Patients and Family Members
  
- 2004, 2007              Consultations for organizations such as the Massachusetts Hospital Association, the Massachusetts Department of Mental Health and Smoke Free UK regarding smoking cessation treatment for patients with major mental illness and conversion to smoke-free psychiatric hospitals and smoke-free inpatient psychiatric units within general hospitals
  
- 2007                      The Brain Addiction Connection  
MGH Schizophrenia Education Day Lectures to Patients and Family Members
  
- 2007                      How Brain Research is Leading to New Treatments to Improve Attention, Memory and Enjoyment of Life  
MGH Schizophrenia Education Day Lectures to Patients and Family Members
  
- 2008                      Symposium Speaker: Cardiovascular Morbidity and Smoking Cessation in Schizophrenia. From the Neck Down  
National Alliance for Mental Illness (NAMI) National Convention, Orlando FL
  
- 2008 – 2011              Consultant on monthly teleconferences with members of the National Alliance for the Mentally Ill (NAMI), a family organization for those with major mental illness. The conference calls provide a forum for parents to ask questions of experts in the field.
  
- 2009                      Neurobiology of Addiction: Addiction is a Brain Disease  
MGH Addiction Education Day Lectures to Employee Assistance Counselors.

Management of Alcohol and Other Substance Use Among Adolescents: A free public education program by the Massachusetts General Hospital Psychiatry Academy Patient and Family Education Program designed for patients and families

- 2009 – Present Consultations to leadership at local colleges and universities on conversion to smoke-free campuses.
- 2010 The Biology of Addiction and Implications for New Treatments  
A free public education program by the Massachusetts General Hospital Psychiatry Academy Patient and Family Education Program designed for patients and families
- 2011 Addiction Treatment in Schizophrenia;  
A free Massachusetts General Hospital Patient and Family Education Program held at MGH
- 2011 The Biology of Addiction, Just Say No?  
A free Massachusetts General Hospital Patient and Family Education Program held at the Harvard Club of Boston
- 2012 Habits to Addictions: Can't Say No?  
A Woman's World of Health Luncheon and Lecture  
Palm Beach, Florida

### **Educational Material for Patients and the Lay Community**

#### **Books, monographs, articles and presentations in other media**

06/1999	Nicotine and Smoking Cessation in Schizophrenia	Massachusetts Alliance for the Mentally Ill Newsletter Spring, 1999 and the Berkshire Alliance for the Mentally Ill Newsletter Summer 1999	<b>Evins AE</b>
03/2004	Treatment for Schizoaffective Disorder	The Infinite Mind Radio Program	Ghaemi SN, <b>Evins AE</b> , Cather C, Goodwin FK.
04/2006	Bupropion helps people with schizophrenia quit smoking	NIDA Notes Vol 20, No 5	L. Whitten interview with <b>Evins, AE</b>
03/2008	Nicotine Dependence in Schizophrenia: Prevalence, Mechanisms, and Implications for Treatment	Psychiatric Times	<b>Evins, AE</b>
2008	Nicotine dependence in schizophrenia: Prevalence, mechanisms, and implications for treatment	<i>Psychiatric Times: Schizophrenia Special Report.</i>	<b>Evins AE.</b>
06/2009	Why it's harder to quit smoking when you're depressed	The Oprah Magazine <a href="http://www.oprah.com/health/Quitting-Smoking-and-Depression">http://www.oprah.com/health/Quitting-Smoking-and-Depression</a>	A. L. Ball interview with <b>Evins, AE</b>



11/2010	Protect the tobacco industry's most vulnerable targets: kids.	Boston Globe Letter to the Editor	<b>Evins, AE</b>
6/2011	FDA cigarette warning labels pack new punch	ABC World NEWS <a href="http://abcnews.go.com/Health/Wellness/fda-cigarette-warning-labels-pack-punch/story?id=13887129#.UJrTH2mMFv0">http://abcnews.go.com/Health/Wellness/fda-cigarette-warning-labels-pack-punch/story?id=13887129#.UJrTH2mMFv0</a>	L. Salah interview with <b>Evins, AE</b>
1/2012	Nicotine may help combat memory loss	My Health News Daily <a href="http://www.myhealthnewsdaily.com/2089-nicotine-combat-memory-loss.html">http://www.myhealthnewsdaily.com/2089-nicotine-combat-memory-loss.html</a>	C. Hatch interview with <b>Evins, AE</b>
9/2012	Varenicline: Where are we today?	Webcast <a href="http://lecture.ucsf.edu/ETS/Play/29824b450a554eca87a1e81ef87e23b31d">http://lecture.ucsf.edu/ETS/Play/29824b450a554eca87a1e81ef87e23b31d</a>	
9/2012	Kicking pot habit can lead to withdrawal, too	ABCNews <a href="http://abcnews.go.com/Health/kicking-pot-habit-leadwithdrawal/story?id=17333197">http://abcnews.go.com/Health/kicking-pot-habit-leadwithdrawal/story?id=17333197</a>	J. Wong interview with <b>Evins, AE</b>
1/2013	Legalizing marijuana raises health concerns	New York Times Health / Science <a href="http://well.blogs.nytimes.com/2013/01/07/legalizing-of-marijuana-raises-health-concerns/">http://well.blogs.nytimes.com/2013/01/07/legalizing-of-marijuana-raises-health-concerns/</a>	Roni Rabin interview with <b>Evins, AE</b>
5/2013	Marijuana is a risky habit we shouldn't encourage	New York Times Opinion Page Room for Debate: <a href="http://www.nytimes.com/roomfordebate/2013/05/22/how-can-marijuana-be-sold-safely/marijuana-is-a-risky-habit-we-shouldnt-encourage">http://www.nytimes.com/roomfordebate/2013/05/22/how-can-marijuana-be-sold-safely/marijuana-is-a-risky-habit-we-shouldnt-encourage</a>	<b>Evins, AE</b>
1/2014	Extended smoking cessation treatment may help schizophrenia, bipolar patients	Reuters Health <a href="http://www.newsdaily.com/canada/8f6de14727adc00b6e40823b0964075c/extended-smoking-cessation-treatment-may-help-schizophrenia-bipolar-patients">http://www.newsdaily.com/canada/8f6de14727adc00b6e40823b0964075c/extended-smoking-cessation-treatment-may-help-schizophrenia-bipolar-patients</a>	Anne Harding interview with <b>Evins, AE</b>
6/2014	Did Colorado go too far with pot? Legalization is premature	New York Times Opinion Page Room for Debate: <a href="http://www.nytimes.com/roomfordebate/2014/06/05/did-colorado-go-too-far-with-pot/problems-cant-be-avoided-if-marijuana-is-legal">http://www.nytimes.com/roomfordebate/2014/06/05/did-colorado-go-too-far-with-pot/problems-cant-be-avoided-if-marijuana-is-legal</a>	<b>Evins, AE</b>
6/2014	The link between weed and schizophrenia is way more complicated than we thought	The Verge <a href="http://www.theverge.com/2014/6/24/5836762/the-link-between-weed-and-schizophrenia-is-way-more-complicated-than">http://www.theverge.com/2014/6/24/5836762/the-link-between-weed-and-schizophrenia-is-way-more-complicated-than</a>	Arielle Duhaime-Ross interview with <b>Evins, AE</b>

## Report of Scholarship

### Publications

#### Peer reviewed publications in print or other media

#### Original Research

1. **Evins AE**, Amico ED, Goff DC. Clozapine treatment increases serum glutamate compared to conventional neuroleptics. *J Neural Transm*. 1997;104:761-766. PMID: 9444574
2. Goff DC, Henderson DC, **Evins AE**, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. *Biol Psychiatry*. 1999 Feb;45(4):512-514. PMID: 10071726
3. **Evins AE**, Fitzgerald S, Wine L, Rosselli R, Goff DC. A placebo controlled trial of glycine added to clozapine in schizophrenia. *Am J Psychiatry*. 2000 May;157:826-828. PMID: 10784481
4. Frankle G, Shera D, Berger-Hershkowitz H, **Evins A**, Connolly C, Goff DC, Henderson DC. Clozapine-Associated Reduction in Arrest Rates of Psychotic Patients With Criminal Histories. *Am J Psychiatry*. 2001 Feb; 158:270-274. PMID: 11156810
5. **Evins AE**, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. *Nicotine Tob Res*. 2001 Nov;3(4):397-403. PMID: 11694208
6. **Evins AE**, Goff DC, Amico E, Posever T, Toker R. D-cycloserine added to risperidone in patients with schizophrenia. *Schizophr Res*. 2002 Jul;56(1-2):19-23. PMID: 12084415
7. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, **Evins AE**, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. *Biol Psychiatry*. 2002 Mar;51(6):493-497. PMID: 11922885
8. Fava M, **Evins AE**, Dorer DJ, Schoenfeld DJ. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. *Psychother Psychosom*. 2003 May-Jun;72(3):115-127. PMID: 12707478
9. **Evins AE**, Cather C, Rigotti NA, Freudenreich O, Henderson DC, Olm-Shipman CM, Goff DC. Two-year follow up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. *J Clin Psychiatry*. 2004 Mar;65(3):307-311. PMID: 15096068
10. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, **Evins AE**, Henderson DC, Baer L, Coyle J. Folate, homocysteine, and negative symptoms in schizophrenia. *Am J Psychiatry*. 2004 Sep;161(9):1705-1708. PMID: 15337665
11. Freudenreich O, Cather C, **Evins AE**, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients towards psychiatric medications: relationship to clinical variables and insight. *J Clin Psychiatry*. 2004 Oct;65(10):1372-1376. PMID: 15491241
12. Henderson DC, Cagliero E, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, Louie PM, **Evins E**, Freudenreich O, Hayden D, Goff DC. Glucose metabolism in schizophrenia patients treated with atypical antipsychotics: a frequently sampled intravenous glucose tolerance test and minimal model analysis. *Arch Gen Psychiatry*. 2005 Jan;62:19-28. PMID: 15630069

13. **Evins AE**, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, Henderson DC, Schoenfeld DA, Goff DC, Rigotti NA. A double-blind, placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. *J Clin Psychopharmacol*. 2005 Jun;25(3):218-225. PMID: 15876899
14. Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson D, Freudenreich O, **Evins AE**, Yovel I, Zhang H, Schoenfeld D. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. *Psychopharmacology*. 2005 Apr;179(1):144-150. PMID: 15502972
15. Henderson DC, Copeland PM, Daley TB, Borba CP, Weber MT, Allison D, **Evins AE**, Schoenfeld D, Anderson EJ, Hayden D, Goff DC. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. *Am J Psychiatry*. 2005 May;162(5):954-962. PMID: 15863798
16. **Evins AE**, Deckersbach T, Cather C, Freudenreich O, Culhane MA, Henderson DC, Green MF, Schoenfeld DA, Rigotti NA, Goff DC. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. *J Clin Psychiatry*. 2005 Sep;66(9):1184-1190. PMID: 16187778
17. Henderson DC, Nguyen DD, Copeland PM, Hayden D, Borba CP, Louie PM, Freudenreich O, **Evins AE**, Cather C, Goff DC. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. *J Clin Psychiatry*. 2005 Sep;66(9):1116-1121. PMID: 16187768
18. Freudenreich O, Herz L, Deckersbach T, **Evins AE**, Henderson DC, Cather C, Goff DC. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. *Psychopharmacology*. 2005 Sep; 181(2):358-363. PMID: 15778880
19. **Evins AE**, Nierenberg AA, Demopulos C, Eisner LR, Sachs GS. Donepezil augmentation of lithium or valproate for treatment resistant mania. *Bipolar Disord*. 2006 Feb;8:75-80. PMID: 16411983
20. **Evins AE**, Demopulos C, Yovel I, Culhane M, Ogutha J, Grandin LD, Nierenberg AA, Sachs GS. Inositol augmentation of lithium or valproate for bipolar depression. *Bipolar Disord*. 2006 April;8(2):168-174. PMID: 16542187
21. Henderson DC, Borba CP, Daley TB, Boxill R, Nguyen DD, Culhane MA, Louie P, Cather C, **Evins AE**, Freudenreich O, Taber SM, Goff DC. Dietary intake profile of patients with schizophrenia. *Ann Clin Psychiatry*. 2006 Apr-Jun;18(2):99-105.
22. Henderson DC, Kunkel L, Nguyen DD, Borba CP, Daley TB, Louie PM, Freudenreich O, Cather C, **Evins AE**, Goff DC. An exploratory open label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. *Acta Psychiatr Scand*. 2006 Feb;113(2):142-147. PMID: 16423166
23. Henderson DC, Copeland PM, Nguyen DD, Borba CP, Cather C, **Evins AE**, Freudenreich O, Baer L, Goff DC. Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. *Acta Psychiatr Scand*. 2006 Feb;113(2):121-125.

24. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, **Evins AE**, Zhang H, Hayden D, Freudenreich O, Cather C, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. *J Clin Psych* 2006 May;67(5):789-797. PMID: 16841629
25. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, **Evins AE**, Goff DC. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. *Acta Psychiatrica Scandinavica* 2007 Feb;115(2):101-105. PMID: 17244173
26. **Evins AE**, Cather C, Freudenreich O, Birnbaum A, Culhane MA, Horowitz J, Zhang H, Hsieh E, Henderson DC, Schoenfeld DA, Rigotti NA, Goff DC. A 12-week, double-blind, placebo-controlled trial of bupropion SR added to nicotine replacement therapy for smoking cessation in schizophrenia. *J Clin Psychopharmacology*. 2007 Aug; 27(4):380-386. PMID: 17632223
27. Fan X, Henderson DC, Chiang E, Cather C, Freudenreich O, **Evins AE**, Goff DC. Sexual functioning, psychopathology and quality of life in patients with schizophrenia. *Schizophr Res*. 2007 Aug; 94(1-3):119-127. PMID: 17590315
28. David SP, Strong D, Brown RA, Lloyd-Richardson EE, **Evins EA**, Wiley to EP, Shields PG, Lerman C, Niaura R. Bupropion efficacy for smoking cessation is influenced by the *DRD2-Taq1A* polymorphism. *Nicotine and Tob Res* 2007 Dec;9(12):1251-1257. PMID: 18058343
29. Fan X, Henderson DC, Nguyen DD, Cather C, **Evins AE**, Freudenreich O, Goff DC. Post traumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. *Psychiatry Res*. 2008 May 30;159(1-2):140-146. PMID: 18423611
30. Freudenreich O, Tranulis C, Cather C, Henderson DC, **Evins AE**, Goff DC. Depressive symptoms in schizophrenia outpatients – prevalence and clinical correlates. *Clin Schizophr Relat Psychoses*, 2008 Jul; 2(2):127-135.
31. Perlis RH, Holt DJ, Smoller JW, Blood AJ, Lee S, Kim BW, Lee MJ, Sun M, Makris N, Kennedy DK, Rooney K, Dougherty DD, Hoge R, Rosenbaum JF, Fava M, Gusella J, Gasic GP, Breiter HC; Phenotype Genotype Project on Addiction and Mood Disorders Collaborators: Rosen B, Salat D, Fischl B, Holt D, **Evins AE**, Caviness V, Iosifesus D, Rooney K, Kim MJ, Loehr VG, Holt D, Caviness V Jr, Myers R, Clark T, Iosifescu DV, Lissot T, Lee S, Calhoun J, Kim MJ, Baxter C. Association of a polymorphism near CREB1 with differential aversion processing in the insula of health participants. *Arch Gen Psychiatry*. 2008 Aug;65(8):882-892.
32. Pizzagalli DA, **Evins AE**, Schetter EC, Frank MJ, Patjas PE, Santesso DL, Culhane MA. Single dose of a dopamine agonist impairs reinforcement learning in humans: Behavioral evidence from a laboratory-based measure of reward responsiveness. *Psychopharmacology*. 2008 Feb; 196(2):221-232. PMID: 17909750
33. Jubelt LE, Barr RS, Goff DC, Logvinenko T, Weiss AP, **Evins AE**. Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. *Psychopharmacology*. 2008 July;199(1):89-98. PMID: 18548234
34. Culhane MA, Schoenfeld DA, Barr RS, Cather C, Deckersbach T, Freudenreich O, Goff DC, **Evins AE**. Predictors of early abstinence in smokers with schizophrenia. *J Clin Psychiatry*. 2008 Nov;69(11):1743-1750. PMID: 19026259

35. Loebel T, Angarita GA, Pachas GN, Huang KL, Lee SH, Nino J, Logvinenko T, Culhane MA, **Evins AE**. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. *J Clin Psychiatry*. 2008 March; 69(3):480-486. PMID: 18294021
36. **Evins AE**, Culhane MA, Alpert JE, Pava J, Liese BS, Farabaugh A, Fava M. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. *J Clin Psychopharmacology*. 2008 Dec;28(6):660-666. PMID: 19011435
37. Goff DC, Cather C, Gottleib JD, **Evins AE**, Walsh JP, Raeke L, Otto MW, Schoenfeld D, Green MF. Once weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study. *Schizophr Res*. 2008 Dec;106(2-3):320-327. PMID: 18799288
38. Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, Goff DC, **Evins AE**. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. *Schizophr Res*. 2008 Jul; 102(1-3):88-95. PMID: 18325740
39. Makris N, Gasic GP, Kennedy DN, Hodge SM, Kaiser JR, Lee MJ, Kim BW, Blood AJ, **Evins AE**, Seidman LJ, Iosifescu DV, Lee S, Baxter C, Perlis RH, Smoller JW, Fava M, Breiter HC. Cortical thickness abnormalities in cocaine addiction--a reflection of both drug use and a pre-existing disposition to drug abuse? *Neuron*. 2008 Oct 9;60(1):174-188. PMID: 18940597
40. Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, Kelly JF, Freudenreich O, Goff DC, **Evins AE**. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. *Neuropsychopharmacology*. 2008 Feb; 33(3):480-490. PMID: 17443126
41. Barr RS, Pizzagalli, DA, Culhane MA, Goff DC, **Evins AE**. A single dose of nicotine enhances reward responsiveness in nonsmokers: Implications for development of dependence. *Biol Psych*. 2008 June 1; 63(11):1061-1065. PMID: 17976537
42. Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Freudenreich O, Cather C, **Evins AE**, Goff DC. Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine. *J Psychiatric Practice*. 2009 Jul;15(4):251-261. PMID: 19625881
43. Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, **Evins AE**, Goff DC. A double blind, placebo- controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. *Acta Psychiatrica Scandinavica*. 2009 Jun;119(6):457-465. PMID: 19183127
44. Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, Miley K, Boxill R, Freudenreich O, Cather C, **Evins AE**, Goff DC. Ziprasidone as an adjuvant for clozapine- or olanzapine- associated medical morbidity in chronic schizophrenia. *Human Psychopharmacol*. 2009 Apr;24(3):225-232. PMID: 19283774
45. Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, Freudenreich O, Cather C, **Evins AE**, Goff DC. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. *J Clin Psychopharmacology*. 2009 Apr;29(2):165-169. PMID: 19512978

46. Goff DC, Cather C, Freudenreich O, Henderson DC, **Evins AE**, Culhane MA, Walsh JP. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. *Psychopharmacology*. 2009 Jan;202(1-3):411-417. PMID: 18716761
47. Santesso DL, **Evins AE**, Frank MJ, Cowman Schetter EM, Bogdan R, Pizzagalli DA. Single dose of a dopamine agonist impairs reinforcement learning in humans: evidence from event-related potentials and computational modeling of striatal-cortical function. *Human Brain Mapping*. 2009 Jul;30(7):1963-1976. PMID: 18726908
48. Freudenreich O, Henderson DC, Macklin EA, **Evins AE**, Fan X, Cather C, Walsh JP, Goff DC. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. *J Clin Psychiatry*. 2009 Dec;70(12):1674-1680. PMID: 19689921
49. Kaufman MJ, Prescott AP, Ongur D, **Evins AE**, Barros TL, Medeiros CL, Covell J, Wang L, Fava M, Renshaw PF. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. *Psychiatry Res*. 2009 Aug 30;173(2):143-149. PMID: 19556112
50. Janes AC, deB. Frederick B, Richardt S, Burbridge C, Merlo-Pich E, Renshaw PF, **Evins AE**, Fava M, Kaufman MJ. Brain fMRI responses to smoking-related images prior to and during nicotine replacement therapy-maintained smoking abstinence. *Exp Clin Psychopharmacol*. 2009 Dec;17(6):365-373. PMID: 19968401
51. Freudenreich O, Brockman M, Henderson DC, **Evins A.E.**, Fan X, Walsh JP, Goff DC. Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). *Psychiatry Res*. 2010 Apr 30;176(2-3):99-102. PMID: 20132993
52. Henderson DC, Sharma B, Fan X, Copeland PM, Borba CP, Freudenreich O, Cather C, **Evins AE**, Goff DC. Dietary saturated fat intake and glucose metabolism impairments in non-diabetic non-obese patients with schizophrenia on clozapine or risperidone. *Ann Clin Psychiatry*. 2010 Feb;22(1):33-42. PMID: 20196981
53. Janes AC, deB. Frederick B, Richardt S, Chuzi S, Pachas GN, Culhane MA, Holmes A, Fava M, **Evins AE\*\***, Kaufman MJ\*\*. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. *Biol Psychiatry*. 2010 Apr 15;67(8):722-729. PMID: 20172508\*\* Contributed equally.
54. Janes AC, deB. Frederick B, Pizzagalli DA, Fava M, **Evins AE\*\***, Kaufman MJ\*\*. Neural substrates of attentional bias for smoking-related cues: an fMRI study. *Neuropsychopharmacology* 2010, Nov;35(12):2339-2345. PMID: 20703221 \*\* Contributed equally.
55. Iovieno N, Tedeschini E, Bentley KH, **Evins AE**, Papakostas GI. Antidepressants for major depressive disorder and dysthymic disorder in patients with co-morbid alcohol use disorders: A meta-analysis of placebo-controlled randomized trials. *J Clin Psychiatry*. 2011 Aug;72(8):1144-1151. PMID: 21536001
56. Mashhoon Y, Janes AC, Jensen JE, Prescott AP, Pachas GN, Renshaw PF, Fava M, **Evins AE\*\***, Kaufman MJ\*\*. Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011 Aug 15;35(7):1709-1713. PMID 21616118. \*\*Contributed equally

57. **Evins AE**, Pachas GN, Mischoulon D, Urbanoski K, Carlini SV, Sousa J, Bentley K, Rigotti NA, Nino-Gomez J, Loebel T, Janes AC, Kaufman MJ, Fava M. A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. *J Clin Psychopharmacol*. 2011 Oct;31(5):597-602. PMID 21869693.
58. Weiner E, Ball MP, Gold JM, **Evins AE**, McMahon RP, Buchanan RW. Bupropion SR Added to group support for smoking cessation in schizophrenia new data and a meta-analysis: Bupropion and group for smoking in schizophrenia. *J Clin Psychiatry*. 2012 Jan;73(1):95-102. PMID 21535998.
59. Dutra SJ, Stoeckel LE, Carlini SV, Pizzagalli DA\*\*, **Evins AE\*\***. Varenicline as a smoking cessation aid in schizophrenia: Effects on smoking behavior and reward sensitivity. *Psychopharmacology*. 2012 Jan;219(1):25-34. PMID 21695488. \*\* Contributed equally
60. Janes AC, Smoller JW, David SP, deB. Frederick, B, Fava M, **Evins AE\*\***, Kaufman MJ\*\*. Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. *Drug Alcohol Depend*. 2012 Jan 1;120(1-3):7-13. PMID 21764527. \*\*Contributed equally
61. Pachas GN, Cather C, Pratt SA, Hoepfner B, Nino J, Carlini SV, Achtyes ED, Lando H, Mueser KT, Rigotti NA, Goff DC, **Evins AE**. Varenicline for smoking cessation in schizophrenia: Evidence for safety, tolerability and efficacy. *J Dual Diag*. 2012 8(2): 117-125. PMID: 22888309.
62. Witte J, Bentley K, **Evins AE**, Clain AJ, Baer L, Pedrelli P, Fava M, Mischoulon D. A double blind, randomized, placebo controlled pilot study of acamprosate for treatment of major depressive disorder in patients with alcohol abuse or dependence. *J Clin Psychopharmacology*. 2012 Dec;32(6):787-796. PMID: 23131884
63. Cather C, Dyer MA, Burrell HA, Goff DC, **Evins AE**. An open trial of relapse prevention therapy for smokers with schizophrenia. *J Dual Diagnosis*. 2013;9(1):87-93. PMID: 23750123
64. Barake M, **Evins AE**, Stoeckel LS Pachas GN, Natchigall LB, Miller KK, Biller BMK, Tritos NA, Klibanski A. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia. 2013 Mar 16 *epub ahead of print, Pituitary*. PMID: 23504371
65. Schuman-Olivier Z, Hoepfner BB, **Evins AE**, Brewer J. Finding the right match: Mindfulness training may potentiate the therapeutic effect of non-judgment of inner experience on smoking cessation. *Substance Use and Misuse*. 2014 Apr; 49(5):586-94. PMID: 24611853
66. Roh S, Hoepfner SS, Fullerton CA, Stoeckel LE, **Evins AE**. Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. *Psychopharmacology (Berl)*. 2014 231: 765-775. PMID: 24114425
67. **Evins AE**, Cather C, Pratt SA, Pachas GN, Hoepfner S, Goff DC, Achtyes ED, Ayer D, Schoenfeld DA. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: A randomized clinical trial. *JAMA*. 2014 311(2):145-154. PMID: 22888309

68. Stoeckel LE, Whitfield-Gabrieli S, **Evins AE**<sup>\*\*</sup>, Gabrieli JD<sup>\*\*</sup>. Development of rt-fMRI Neurofeedback as a clinical tool: Demonstrated potential and remaining challenges. *In press, Neuroinformatics*. <sup>\*\*</sup>Contributed equally
69. Gilman JM, Curran MT, Calderon V, Stoeckel LE, **Evins AE**. Social influence increases temporal discounting rates in young adults. *In press, PLoS One*.
70. Stoeckel LE, Garrison KA, Ghosh S, Wighton P, Hanlon CA, Gilman JM, Greer S, Turk-Brown N, deBettencourt MT, Scheinost D, Craddock C, Thompson T, Calderon V, Bauer CC, George M, Breiter HC, Whitfield-Gabrieli S, Gabrieli JD, LaConte S, Hirshberg L, Brewer JA, Hampson M, van der Kuwe A, Mackey S, **Evins AE**, Optimizing real time fMRI neurofeedback for therapeutic discovery and development. *In press, Neuroimage: Clinical*.
71. Pachas GN, Gilman JM, Orr SP, Hoepfner B, Carlini SV, Loebel T, Nino J, Pitman RK, **Evins AE**. Memory reconsolidation blockade with single dose propranolol does not effect physiologic or emotional reactivity to smoking cues. *In press, Psychopharmacology*.

*Original reports under review*

72. Stoeckel LE, Palley LS, Gollub RL, Neimi SM, **Evins AE**. Patterns of brain activation when mothers view their own child and dog: A pilot fMRI study. *In revision, PLoS One*.
73. Wang R, Schoenfeld DA, Hoepfner, B, **Evins AE**. Detecting treatment-covariate interactions using permutation methods. *In revision, Statistics in Medicine*.
74. Stoeckel LE, Chai XJ, Zhang J, Whitfield-Gabrieli S, **Evins AE**. Brain structural and functional connectivity differences between smokers and never-smokers associated with smoking behavior. *Under review, Biology of Addiction*.
75. Gilman J, Treadway M, Curran MT, Calderon V, **Evins AE**. Effect of social conformity on effort-allocation for monetary rewards. *Under review, Cognitive, Affective, and Behavioral Neuroscience*.
76. Schuman-Olivier Z, Hoepfner BB, Pachas GN, **Evins AE**. Remembering the moment, forgetting to record: Feasibility of measuring meditation using accelerometer-based ecological momentary assessment. *Under review, Psychology of Addictive Behaviors*

**Reviews**

1. Goff DC, **Evins AE**. Negative symptoms in schizophrenia: neurobiological models and pharmacological response. *Harv Rev Psychiatry*. 1998 Jul-Aug;6(2):59-77. PMID: 10370450
2. Goff DC, Cather C, **Evins AE**, Henderson DC, Freudenreich O, Copeland PM, Bierer M, Duckworth K, Sachs F. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. *J Clin Psychiatry*. 2005 Feb; 66(2):183-194; quiz 147, 273-274. PMID: 15705003
3. David S, Lancaster T, Stead LF, **Evins AE**. Opioid antagonists for smoking cessation. *Cochrane Database of Systematic Reviews*. 2006 Oct 18;(4):CD003086). PMID: 17054160



4. Gelenberg AJ, de Leon J, **Evins AE**, Parks JJ, Rigotti NA. Smoking cessation in patients with psychiatric disorders. *J Clin Psychiatry*. 2007 Sep;68(9): 1404-1410.
5. David SP, Lancaster T, Stead LF, **Evins AE**, Prochaska JJ. Opioid antagonists for smoking cessation. *Cochrane Database of Systematic Reviews* 2013, Issue 5. Art. No.: CD003086. DOI: 10.1002/14651858.CD003086.pub2.
6. David SP, Lancaster T, Stead LF, **Evins AE**, Prochaska JJ. Systematic Review and Meta-Analysis of Opioid Antagonists for Smoking Cessation. *BMJ Open*. 2014; Mar 14;4(3):e004393. doi: 10.1136/bmjopen-2013-004393. PMID: 4633528
7. **Evins AE**, Cather C, Laffer A. Treatment of nicotine dependence in people with psychiatric illness: Toward clinical best practices. *In press, Harv Rev Psychiatry*.

### **Clinical Communications**

1. **Evins AE**, Tisdale TA. Bupropion for smoking cessation in schizophrenia. *Am J Psychiatry*. 1999;156(5):798-799. PMID: 10327924
2. **Evins AE**, Goff DC. Varenicline treatment for smokers with schizophrenia. *J Clin Psychiatry*. 2008 Jun;69(6):1016. PMID: 18683999

### **Non-peer reviewed scientific or medical publications/materials in print or other media**

### **Invited Reviews and Commentaries**

1. **Evins AE**, Goff DC. Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. *CNS Drugs*. 1996;6(2):130-147.
2. **Evins AE**. Update in Psychiatry Audiotape Series: Antidepressant medications in the treatment of negative symptoms of schizophrenia. November, 1997.
3. **Evins AE**. Clozapine in treatment refractory schizoaffective disorder. *Institutional Psychiatry*. 2000;1(13-14).
4. Goff DC, Freudenreich O, **Evins AE**. Augmentation strategies in the treatment of schizophrenia. *CNS Spectr*. 2001;6(11):904-911. PMID: 15328472.
5. **Evins, AE**. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. *J Clin Psychiatry Suppl*. 2003;64(Suppl8):9-14. PMID: 12892536
6. Barr RS, **Evins AE**. Cognitive dysfunction and clinical outcome in schizophrenia. *Dir Psychiatry*. 2006;26(1):17-31.
7. Dyer M, Barr RS, **Evins AE**. Nicotinic and glycinergic medications for disorders of hedonic dysregulation. *Lett Drug Design Discov*. 2007 July;4(5):373-381.
8. Cather CA, Barr RS, **Evins AE**. Smoking and schizophrenia: prevalence, mechanisms and implications for treatment. *Clinical Schizophrenia and Related Psychoses*. 2008 April;2(1):70-78.

9. **Evins, AE.** Bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia. *Evidence Based Mental Health.* 2010 Nov; 13(4):120. PMID: 21036982.
10. Roh S, **Evins, AE.** Possible role of nicotine for the treatment of mild cognitive impairment. *Expert Rev Neurotherapeutics.* 2012 12(5), 531-533. PMID 22550981.
11. **Evins AE,** Green AI, Kane JM, Murray RM. Does using marijuana increase the risk for developing schizophrenia? *J Clin Psychiatry.* 2013 Apr; 74(4):e08. PMID: 23656852.
12. **Evins AE.** Reassessing the safety of varenicline. *Am J Psychiatry.* 2013; 170:1385-1387. PMID: 24306334

### **Chapters**

1. Perlis RH, **Evins AE,** Sachs GA. The role of atypical neuroleptics in bipolar disorder, in Bipolar Disorder: A Clinicians' Guide to Biological Treatments. 2002;Editor: Yatham L. Taylor & Francis:167-183.
2. Yeterian J, Pachas G, **Evins AE,** Kelly J. Rating Scales for Alcohol and Nicotine Addiction. In Baer L, Blais MA, editors. Handbook of Clinical Rating Scales Assessment in Psychiatry and Mental Health. Totowa NJ: Humana Press Inc. 2009.
3. Schuman-Olivier Z, Stoeckel LE, Weisz E, **Evins AE.** Smoking Effects in the Human Nervous System. *Chapter 11, pages 333-366.* In "The Effects of Drug Abuse on the Human Nervous System", Madras B, Kuhar M., Editors. Copyright 2014, Elsevier, Boston. ISBN 978-0-12-4186798.

### **Clinical Communications**

1. O'Donnell WJ, Kradin RL, **Evins AE,** Wittram C. Case records of the Massachusetts General Hospital. Weekly Clinicopathological Exercises. Case 39-2004. A 52-year-old woman with recurrent episodes of atypical pneumonia. *N Engl J Med.* 2004;351(26):2741-2749. PMID: 15616209
2. Gelenberg AJ, de Leon J, **Evins AE,** Parks JJ, Rigotti NA. Smoking cessation in patients with psychiatric disorders. Primary Care Companion *J Clin Psychiatry* 2008;10(1): 52-58. PMID: 18311422.
3. **Evins AE,** Green AI, Kane JM, Murray RM. Commentary: The effect of marijuana use on the risk for schizophrenia. *J Clin Psychiatry* 2012; 2012 Nov;73(11):1463-1468. PMID: 23218162

### **Professional educational materials or reports, in print or other media**

1. **Evins AE.** Standard Care Treatment Recommendations for Schizoaffective Disorder. Web Based Training Course. MGH Bipolar Treatment and Research Center. October, 2000.
2. **Evins AE.** Use of Novel Antipsychotic Medications in Schizoaffective Disorder. Web Based Training Course. [www.manicdepressive.org](http://www.manicdepressive.org). MGH Bipolar Treatment and Research Center. February, 2000.
3. **Evins AE.** Novel Anticonvulsant Medications: Evidence for Efficacy in Bipolar Mood Disorders. Audiotape Educational Program. July, 2001.
4. Gottlieb JD, **Evins AE.** Nicotine dependence treatment for smokers with schizophrenia, A practical guide for clinicians. *Current Psychiatry*. 2007 July;6(7): 65-77.
5. Prochaska JJ, Benowitz N, Singh S, **Evins AE.** Varenicline: Where are we today? Webcast sponsored by University of California Office of the President Tobacco Related Disease Research Program. September, 2012.

### **Clinical Guidelines and Reports**

1. Zarate C, Barreira P, Blum N, Duckworth K, **Evins AE**, Flannery RB, Hanson MA, Moran D, Musgrave J, Rofman ES, Slayton J, Sousa S. Commonwealth of Massachusetts Executive Office of Health and Human Services Clinical Practice Guidelines for the Treatment of Bipolar Disorder in Adults. June, 2002.

### **Theses**

Cowman E, **Evins AE**, Pizzagalli DA. The effects of a D2/D3 agonist, pramipexole, on reward responsivity in normal adults. 2005 Undergraduate Thesis, Harvard University Department of Psychology. Thesis awarded High Honors and awarded the Psychology Department Faculty Award at the Harvard University Psychology Department Thesis Day, April 26, 2005. Thesis Advisors: Pizzagalli, D., **Evins, A.E.**, Hooley, J.

Raveendran, J. Improving Detection of fMRI-based Brain Activation: Methods and Application to Nicotine Addiction. A thesis presented to the Faculty of the Committee on Degrees in Neurobiology in partial fulfillment of the requirements for the degree with honors of Bachelor of Arts Harvard University Cambridge, Massachusetts. March 2012. Thesis Advisors: **Evins, A.E.**, Stoeckel, L.E.

## **Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings**

1. Stoeckel LE, Chai XJ, Hinds O, Tighe A, Coakley A, Whitfield-Gabrieli S, Gabrieli JD, **Evins AE**. (2011). Real-time fMRI neurofeedback targeting inhibitory control brain activation decreases emotional reactivity to smoking cues in cigarette smokers. American College of Neuropsychopharmacology, 50<sup>th</sup> Anniversary Meeting, Kona, HI, USA.
2. Pachas GN, Carlini S, Milet R, **Evins AE**, Maravic MC. (2011) The Integrated Dual Disorders Treatment (IDDT) Program, Proyecto Tranquilidad. Presented at the 11th Annual International Conference of the National Hispanic Science Network on Drug Abuse, Pathways Toward Health Equities in Hispanic Populations, Coral Gables, FL.
3. Wesnes K, Edgar C, Brownsiein L, Hassman H, **Evins AE**. (2012) The central role of attention and information processing deficits in the profile of cognitive dysfunction in schizophrenia. 52<sup>nd</sup> Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), Phoenix AZ and the 3<sup>rd</sup> Biennial Meeting of the Schizophrenia International Research Society (SIRS) Florence, Italy.
4. Carlini SV, Pachas G, Fava M, **Evins AE**. (2012) Predictors of lapse after initial abstinence with nicotine replacement therapy in female smokers. 18<sup>th</sup> Annual meeting of the Society for Research on Nicotine and Tobacco, Houston, TX.
5. Hearon BA, Burrell HA, Pachas GN, Cather C, Otto MW, **Evins AE**. (2013) Differential effects of varenicline and nicotine replacement therapy on cue-induced cravings in recently-abstinent smokers. Presented at the Massachusetts General Hospital Clinical Research Day, October 2012 and at 19<sup>th</sup> Annual meeting of the Society for Research on Nicotine and Tobacco, Boston, MA.
6. Pachas GN, Schuman-Olivier Z, Hoepfner S, Grasser EB, Daigneault JF, and **Evins, AE**. (2013) Comparison of the effect of mindfulness and cognitive behavioral therapy for smoking cessation on physiological responses to smoking cues and craving. Presented at the Massachusetts General Hospital Clinical Research Day on October 2012 and at 19<sup>th</sup> Annual meeting of the Society for Research on Nicotine and Tobacco, Boston, MA.
7. Schuman-Olivier Z, Pachas GN, Hoepfner B, **Evins AE**. (2013) A randomized controlled trial of mindfulness training for smokers. 19<sup>th</sup> Annual meeting of the Society for Research on Nicotine and Tobacco, Boston, MA.
8. Peechatka AL, Jensen JE, Wang KP, Zickl S, Gansler DA, Kaufman MJ, **Evins AE**, Janes AC. (2014). Dorsal anterior cingulate cortex glutamate levels as an indication of chronic schizophrenia severity. International Neuropsychological Society, Seattle, Washington, USA

## **Narrative**

### **Introduction**

I am a psychiatrist who specializes in treating co-occurring addictive disorders and major psychiatric illness. I direct the MGH Center for Addiction Medicine and Addiction Research Program. I teach residents, fellows and physicians about neurobiology and treatment of addiction in those with serious mental illness, particularly nicotine dependence and schizophrenia. I train post-doctoral research fellows. I serve as a peer reviewer of NIH grants, as a teacher at continuing education courses and conferences, as an editorial board member and as a reviewer for a number of journals.

### **Areas of Excellence, Investigation**

I demonstrated that nicotine dependence treatments are effective for smoking cessation for those with schizophrenia, that high-dose, combination pharmacotherapy is superior to monotherapy for smoking cessation in schizophrenia, that rates of relapse to smoking are high in this population after discontinuation of nicotine dependence treatment, and that extended duration pharmacotherapy for 52 weeks dramatically improves long term abstinence outcomes. The impact of this research has been to change clinical recommendations. 2010 and 2013 Cochrane Reviews are based largely on this work and the 2010 NIMH PORT Evidence Based Guidelines for Treatment of Schizophrenia included a recommendation for the first time for smoking cessation treatment in schizophrenia and cite this work as primary evidence that smokers with schizophrenia who wish to try to quit smoking should be offered pharmacotherapy and behavioral treatment for smoking cessation. This has the potential to reduce the heavy burden of smoking-related disease in this population.

In a related series of trials I have focused on study of innovative treatments for negative symptoms and reward processing and cognitive dysfunction in schizophrenia and in developing treatments for nicotine dependence in this population. Our group has demonstrated that agonists at the strychnine-insensitive glycine site of the NMDA glutamate receptor complex improve negative symptoms of schizophrenia. Inter-individual variability in clinical effectiveness of these agents called into question their clinical utility, so we applied magnetic resonance spectroscopy techniques to correlate change in brain glycine concentration with improvement in negative symptoms, cognitive function and smoking. We demonstrated that brain glutamate concentration can predict smoking cessation outcomes. Our group also showed that transdermal nicotine improves cognitive function and nicotinic receptor antagonists worsen cognition in non-smokers with and without schizophrenia, but to a greater extent in those with schizophrenia.

### **Supporting Activity, Clinical Expertise and Innovation**

In addition to research, I perform clinical work, with a caseload of 150 patients from 1995-2001. Since 2001, I have performed consultations on diagnosis and pharmacological management with a focus on treatment of those with bipolar disorder and schizophrenia, with or without co-occurring substance use disorders. The inspiration for my clinical research has come from these clinical interactions and the desire to improve clinical outcomes in patients with serious mental illness. There were no standard treatments for negative symptoms, cognitive dysfunction or nicotine dependence in schizophrenia when I began my career. I co-founded the Wellness Program in the MGH Schizophrenia Program in 1997 to develop treatments for nicotine dependence and obesity in schizophrenia. With support from the Massachusetts Department of Mental Health, I developed a Tobacco Treatment Network at 8 sites in New England to implement and test smoking cessation treatments for patients with schizophrenia.

### **Teaching Efforts**

My clinical teaching contributions include co-authorship of the DMH 'Guidelines for Psychiatrists for Preventive Medical Management of Patients with Major Mental Illness' and 'Guidelines for Management of Bipolar Disorder'. In addition to individual supervision of psychiatric residents, I have contributed to ongoing courses for medical students, residents, fellows on schizophrenia, nicotine dependence, and co-occurrence of addiction and major mental illness at the local level. I have taught practicing health care professionals at regional, national and international levels through courses and webinars.

